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ABSTRACT

LUNG DISPOSITION MODEL-BASED ANALYSES OF CLINICAL
PHARMACOKINETIC PROFILES FOR INHALED DRUGS

By: Anuja Raut, B.PHARM., M.S.

A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2017

Director: Masahiro Sakagami, Ph.D.
Associate Professor, Department of Pharmaceutics, School of Pharmacy

There has been a desire to accurately interpret the inhaled pharmacokinetic (PK)
profiles of drugs in humans to aid successful inhaled drug and product developments.
However, challenges are layered, as 1) the drug dose delivered to the lung (DTL) from
inhalers is a portion of the formulated dose but rarely determined; 2) lung delivery and
regional deposition differ, depending on drug, formulation and inhaler; 3) drugs are not

only absorbed from the lung but may also be from the gastrointestinal (GI) tract; and 4) in
addition to absorption into the systemic circulation, multiple non-absorptive processes
also eliminate drugs from the lung, such as mucociliary clearance, metabolism,
phagocytosis and tissue binding. Hence, this thesis project aims to develop new lung
disposition model-based analyses to derive the meaningful kinetic descriptors for lung
disposition from inhaled PK profiles in humans.
Two approaches, curve fitting- and moment-based approaches, were developed.
Both approaches modeled the kinetics of lung disposition rate-controlled by absorption
(ka) and non-absorptive loss (knal), assuming no contribution of GI absorption. An
exhaustive literature review found necessary data sets for three drugs, tobramycin,
calcitonin and ciprofloxacin. In the curve fitting-based approach, each inhaled PK profile
was fitted to the lung disposition model, while the DTL was obtained from corresponding
-scintigraphic lung deposition and the kinetic parameters of systemic disposition were
fixed by separate intravenous PK profile model analysis. In the moment analysis-based
approach, the mean lung residence times (MLRT) and the DTL-based bioavailability (FL)
were estimated and used to determine the ka and knal values in the lung disposition model,
given FL = MLRTka = ka/(ka+knal).
The ka and knal values were successfully derived for all the three drugs delivered
by dry powder inhalers (DPIs) and/or nebulizers (NEB) through both approaches. Their
“goodness-of-fit” was reasonably satisfactory. The ka values appeared to be primarily
described by partition-based diffusion affected by the three hydrophilic drug’s molecular
weight. In contrast, the knal values differed, yet appeared to become plausible, with a
notion of additional non-absorptive confoundedness due to lung tissue binding

(tobramycin) and metabolism (calcitonin), in addition to mucociliary clearance. The ka and
knal values derived by the two approaches were comparable in majority of the cases.
The success of these PK modeling analyses enabled further attempts to identify
most influential attributes by simulation. The systemic PK and lung exposure profiles were
predicted by simulation upon ±20 % changes in each of the DTL, ka and knal values to
examine changes in the systemic PK metrics (Cmax, AUC and Tmax) and local lung
exposure metrics (AUClung and LRT0.5). For all three drugs, the Cmax and AUC changes
were identical to changes in the DTL without changing the Tmax. In contrast, impacts of
the ka and knal changes differed between drugs, depending on the relative contribution of
the rate constant to their sum (ka+knal). It appeared that the major contributor of the sum
(ka+knal) was that rate-controlling the kinetics of lung disposition.
In conclusion, this thesis project has successfully proposed two new approaches
of curve fitting and moment-based analysis by accurately deriving the kinetic descriptors
of lung disposition (ka and knal) for three drugs from the inhaled PK profiles in humans.
Their applications were extended to predict likely changes in the systemic PK and local
lung exposure metrics by simulation. While attempts should continue with more drugs,
these approaches are believed to be useful in identifying critical attributes to determine
the lung disposition kinetics and thus predicting the lung kinetic behavior and systemic
PK profiles of new drug entities in humans.

CHAPTER 1
INTRODUCTION

1.1

Inhaled drug delivery
Inhaled drug delivery utilizes the lung as the route of administration primarily for

treating local lung diseases such as asthma, chronic obstructive pulmonary disease
(COPD) and lung infection (Labiris & Dolovich 2003; Patil & Sarasija 2012). It is also used
to deliver drugs to treat systemic diseases like insulin for diabetes mellitus and nicotine
for smoking cessation, while being tested in clinical trials for treating migraine (Patil &
Sarasija 2012; Tfelt-Hansen et al. 2000). Regardless of use for local or systemic disease
treatments, an optimal amount of drug is required to reach the lung by passing through
the oropharyngeal cavity to produce the therapeutic responses following inhalation
(Labiris & Dolovich 2003). This is in contrast to intravenous injection and oral
administration, in which the entire drug dosage is directly injected into the systemic
circulation via needles and taken by the mouth to be swallowed, respectively (Verma et
al. 2010). While intravenous injection is capable of producing the fastest onset of action
in less than 1 min, this route has several disadvantages, which includes a greater risk of
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irreversible adverse effects due to higher systemic concentrations, a higher risk of
embolism, and most critically, pain with needles (Verma et al. 2010). In this context,
inhaled route is needle- and pain-free, and can produce the therapeutic responses as fast
as injection for certain drug molecules, exerting the onset of action in 2-3 min. It is clear
that this pharmacologic rapidity is much shorter than 30-90 min required for oral
administration (Verma et al. 2010).
Unlike intravenous injection and oral administration, however, inhaled drug
delivery requires an appropriate choice and use of inhaler devices for successful local or
systemic therapies (Patil & Sarasija 2012). Most commonly used inhaler devices are
pressurized metered dose inhalers (pMDI), nebulizers (NEB) and dry powder inhalers
(DPI). Each inhaler device requires a patient’s inspiratory effort that potentially causes
variability as to fractions of the formulation dose to reach the lung by inhalation (Ibrahim
et al. 2015). In this regard, training has been shown to be essential not only for proper
use by patients in therapy but also for reproducible delivery among subjects in clinical
pharmacokinetic or bioequivalence studies (Ibrahim et al. 2015).
pMDIs are most commonly used for delivering drug aerosols in the treatments of
asthma and COPD. pMDI is composed of a canister, a metering valve, an actuator and a
mouth piece (Ibrahim et al. 2015). The canisters are made of inert materials such as
plastic, stainless steel, glass and aluminum to hold a high pressure inside to maintain
propellant gas in a liquid state (Newhouse 1991). pMDIs generate aerosol drug doses
from the metering valve by actuation accurately and reproducibly, so that their dose
emission is not influenced by inspiratory force or maneuver of patients (Newhouse 1991).
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NEBs are inhaler devices suitable for use in pediatric, ventilated or unconscious
patients because aerosol delivery does not require actuations and patients’ inspiratory
coordination (Ibrahim et al. 2015). Two types of NEBs, jet and ultrasonic NEBs, are
currently in use, depending on the type of force generating drug aerosol from solutions.
NEBs are bulky, cumbersome inhaler devices, while allowing delivery of large aerosol
doses; however, electric power and long inhalation time are required (Newhouse 1991).
Unlike NEBs, DPIs are portable devices and require little coordination between
patient inspiration and device actuation. Since DPIs formulate and deliver drugs in a dry
powder, greater chemical stability can be achieved. However, the DPI performance
enabling optimal aerosol generation and delivery to the lungs in patients is highly
dependent on drug, formulation and inhaler device (Ibrahim et al. 2015). DPIs employ
external forces like airflow shear or particle-particle and particle-device impaction to
deaggregate and aerosolize the powder drugs. The type of such external forces depends
on the design of DPIs. For example, Diskus, Clickhaler and Multihaler employ airflow
shear, whereas Turbuhaler and Spinhaler rely on particle-particle and particle-device
impaction for drug aerosol generation. Besides, a fair balance of inhaler resistance and
airflow velocity is critical for the best DPI performance. For instance, a higher flow rate
increases generation of aerosols suitable for deposition in the upper respiratory tract
(Ibrahim et al. 2015).
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1.2

Lung deposition and disposition complexities
While inhalation therapy is intended by direct delivery of drugs to the lungs, drug

mass delivered to the lung, regional (peripheral vs. central) lung deposition, drug mass
deposited in the ex-lungs, e.g., oropharynx, and drug mass swallowed to the
gastrointestinal (GI) tract, are all dependent on choice and use of inhaler device (pMDI,
NEB or DPI) in addition to drug and formulation. The GI drug absorption and the liver
metabolism determine how much of the swallowed drugs eventually contribute to the
systemic drug levels (Figure 1.1).

Figure 1.1 The fate of inhaled drugs after inhalation, modified from Hochhaus (2007).

Figure 1.1 shows the fate of drugs after inhalation. When a patient inhales a dose
formulated in an inhaler, only a fraction is emitted, while significant fractions remain in the
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inhaler. Out of the emitted drug dose, some fractions are trapped in the oropharynx or
exhaled by the patient. The fraction deposited in the lung can be subjected to mucociliary
clearance if its rate is faster than that of dissolution (in case of dry powder aerosol) and
cellular uptake for local pulmonary effects or absorption into the systemic circulation for
systemic effects. The fraction deposited in the oropharynx is swallowed into the GI tract.
Depending on its GI absorption and liver metabolism, the drug could reach the systemic
circulation. Hence, the fate of the drug after inhalation depends on the doses deposited
not only in the lung but also in the oropharynx, the kinetics of dissolution and absorption
in the lung and, GI absorption and liver metabolism (Hochhaus 2007).
As described above, regional (peripheral vs. central) deposition within the lung is
also affected by drug, formulation and device characteristics, as well as patient factors,
such as airway geometry, inspiratory profile, breath holding, and correct inhaler use.
However, there are currently no established quantitative understanding between regional
drug deposition in the lung and subsequent kinetics of lung absorption and clearance.
Hence, in addition to the complexity due to inhaler delivery efficiency and patient factors,
this issue of regional lung deposition needs to be taken into account for interpretation of
the PK profile for inhaled drugs. However, such attempts remain theoretical to date, as
described below.
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Figure 1.2 Fate of inhaled drugs following deposition in the lung: (1) Deposition onto
and dissolution into the lung lining fluid (LLF); (2) Absorption across the pulmonary
epithelium; (3) Phagocytic and mucociliary clearance of the undissolved particles; (4)
Local pulmonary metabolism; and (5) Lung tissue binding. The figure is modified from
Ruge et al. (2013).

Upon deposition in the lung as a dry powder aerosol, the drug particles must first
be dissolved in the lung lining fluid (LLF) that covers the lung epithelia, and then taken by
the lung cells and/or absorbed into the systemic circulation. Drug dissolution in the LLF
depends on the drug’s solubility as well as the LLF volume available for dissolution. Given
the lung region-dependent LLF composition, volume and depth, dissolution of inhaled
drugs may be different in different lung regions; however, to date, such knowledge has
not been established (Olsson et al. 2011).
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In general, lipophilic drugs are absorbed across the lung epithelia via passive
diffusion, whereas hydrophilic drugs pass through tight junctions between epithelial cells
(via paracellular route). In addition, drugs can be actively absorbed via solute-like carrier
(SLC) transporter processes as well as endo/trans-cytosis. Therefore, lung absorption
may be comprised of such multiple processes that simultaneously occur at different rates.
Such lung absorption rates may also vary in different lung regions upon deposition. For
instance, drug absorption in the peripheral lung is likely faster due to higher rate of
perfusion, a greater surface area (100 m2) and a thin diffusion epithelial barrier (Borghardt
et al. 2015).
In addition to dissolution and absorption, there are other kinetically competing
processes, which may contribute to clearance of inhaled drugs from the lung. These
include mucociliary clearance, lung metabolism, phagocytic clearance and lung tissue
binding (Labiris & Dolovich 2003; Patton & Byron 2007). When drug particles deposited
in the lung remain insoluble, such particles are trapped in the gel layer of the LLF, cleared
toward the pharynx by an upward mucus movement by cilia beating, and eventually
swallowed to the GI tract. Both the total drug mass deposited in the lung and regional
lung deposition may be different among subjects. Especially in patients with asthma and
COPD, their smaller airway cross-sectional areas cause more impaction in the central
parts of the lung. This results in greater mucociliary clearance loss due to faster cilia
movement in the central lung, compared to the peripheral lung, thereby possibly
explaining a reduced systemic exposure in patients seen for some corticosteroids (Olsson
et al. 2011). Thus, depending on the regional lung deposition as well as lung disease
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state, mucociliary clearance may enable removal of the drugs from the lung before
absorption or local pharmacologic effects.
All the drug-metabolizing enzymes found in the liver are also found throughout the
conducting airways and lung alveoli, yet to a lesser extent. Cytochrome P450 (CYP450)
enzymes, flavin-containing monooxygenases (FMO), monoamine oxidase (MAO),
aldehyde dehydrogenase, NADPH-CYP450 reductase are all found in the lungs. Protein
and peptide drugs are highly degraded by proteases that are found in the lung epithelia,
alveolar macrophages and other inflammatory cells like neutrophils (Labiris & Dolovich
2003). When the drug is susceptible to degradation by such lung’s metabolizing enzymes,
it may contribute as non-absorptive clearance of the drug from the lung.
Drug particles deposited in the alveolar region are cleared by macrophages when
the drugs are insoluble or slowly dissolved and absorbed to the systemic circulation.
These alveolar macrophages phagocytose such drug particles and then translocate them
into the ciliated airways for mucociliary clearance. The alveolar macrophages are also
sources for lung proteases that metabolically degrade proteins and peptides, and the
protease expression may differ, depending on disease states of the lungs, but is largely
unknown (Labiris & Dolovich 2003).
Lipophilic or hydrophilic molecules that carry positive charge under physiological
conditions, such as pentamidine, verapamil and tobramycin, are mostly basic amines,
and thus may bind favorably to the lung tissue, namely via phospholipids or lysosomes
(Patton & Byron 2007). Their lysosomal uptake is caused by trapping, i.e., unionized weak
bases permeate and accumulate in the acidic interior of lysosomes, where the molecules
get protonated and thus cannot diffuse back into the cytosol. The uptake of such basic
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amines into the lysosomes depends on the lysosomal pH (Boer 2003). Thus, lung tissue
binding may lead to slowing down of lung’s mucociliary clearance and in turn possibly
increase the duration of local effects.

1.3

Methods to determine total and regional drug lung deposition
As described previously, only a fraction of the drug dose formulated in an inhaler

device is deposited in the lung after inhalation. Additionally, the regional lung deposition
varies, depending on the drug, formulation and inhaler, along with a variability caused by
patient factors. The drug mass deposited in the lung and regional lung deposition is
therefore of interest of kinetically analyze the systemic PK profile data of inhaled drugs.
In vitro impactor-based testing methods classify inhaler device-generated aerosol
particles, and “respirable” particles are generally defined as those with mass median
aerodynamic diameter (MMAD) between 1 and 5 µm, i.e., “respirable fraction” or “fine
particle fraction” (FPF). The particles larger than that size are “non-respirable” which are
to impact on the oropharynx (after which they are swallowed and may be absorbed from
the GI tract). The simplest apparatus to determine such “respirable” particle mass is the
Twin Impinger, which has an angled “throat” and two collecting chambers, among which
the drug particles reaching the second chamber are classified as “respirable” ones. In
contrast, the Anderson cascade impactor (ACI) allows more detailed collection of inhaler
device-generated aerosol particles into eight size fractionations that precede the rightangled USP induction port. Generally, while reproducible FPF data are important for
quality-control, these in vitro impactor methods possess a number of drawbacks for
prediction of lung deposition, given that the anatomy of the human respiratory tract is
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complex and therefore poorly represented by these collection chambers or plates
alongside their “throat” (Snell & Ganderton 1999; Chrystyn 2001). Daley-Yates et al.
(2014) compared in vitro fine particle mass of Rotahaler and Diskus inhalers for
fluticasone propionate and salmeterol against the in vivo performance of both the inhalers
and found that the in vitro results had poor sensitivity and predictability of in vivo results.
It was observed that even though the in vitro results were comparable for both inhalers,
the in vivo exposure metrics area under the plasma concentration vs. time curve (AUC)
was larger and time for maximum plasma concentration (Tmax) was shorter for Rotahaler
compared to Diskus. This was noted to be probably due to a larger dose delivered to lung
and a greater peripheral deposition from Rotahaler due to a larger dose emission duration
of 3 seconds compared to a mere 0.3 seconds from Diskus. A shorter dose emission
duration may cause greater oropharyngeal and central lung deposition due to impaction
with walls of these regions. However, since in vitro techniques do not closely mimic the
complexity of the human oropharyngeal and respiratory anatomy, they were not found to
be good predictors of in vivo performance of these inhalers.
Conventional pharmacokinetic (PK) analysis is challenging for inhaled drugs,
because the systemic (plasma or serum) drug levels may be confounded by GI absorption
of the swallowed fraction from the oropharyngeal deposition, in addition to lung
absorption. Accordingly, co-administration of activated charcoal can be used to block GI
absorption to reflect the systemic levels exclusively due to lung absorption. Note however
that this becomes important only when the drug has considerable oral bioavailability.
Some studies used the drug mass in urine collected in the first 30 min of inhaled
administration as a quantitative measure of lung deposition and absorption. Even so, the
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rate of absorption across the lung is variable and affected by depth of inspiration and
breath-holding, as well as dissolution in the LLF following regional lung deposition.
Therefore, such approaches best reflect whole lung drug deposition, while giving no
information on lung region-dependent deposition and disposition (Chrystyn 2001).
Imaging techniques like the two dimensional -scintigraphy involve radiolabeling of
inhaled drugs in formulations using a -emitting radioisotope like

99mtechnetium.

The

whole lung, oropharynx and stomach as well as the inhaler device and the exhalation filter
are imaged using a -camera. The method also allows differentiation of “central” and
“peripheral” lungs, thereby estimating not only total lung deposition but also regional lung
deposition. While three-dimensional imaging methods like single photon emission
computed tomography (SPECT) and positron emission tomography (PET) are also
available, they are much more expensive, time consuming, and require highly skilled and
experienced personnel to perform the imaging. As a result, two dimensional
scintigraphy has been most widely used to determine the total and regional lung
deposition (Chrystyn 2001; Snell & Ganderton 1999).

1.4 PK modeling approaches
The total and regional deposition, aerosol drug dissolution, and absorptive and
non-absorptive clearance processes in the lungs have made accurate understanding of
lung disposition for inhaled drugs difficult and challenging. Successful attempts should
derive and predict such complex kinetics of inhaled drugs by incorporating mucociliary
clearance, absorption to the systemic circulation via the lung and the GI tract, and
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dissolution in the LLF (Weber & Hochhaus 2013; Sakagami 2014). A distinction can be
made in the model between central vs. peripheral lung depending on the goal of the
modeling approach. While making this distinction allows accounting for disposition
complexity due to inherent physiological differences in the lung, like faster absorption from
peripheral lung and faster mucociliary clearance rate in the central lung; incorporating this
distinction in the model makes the model more complex and necessitates making certain
assumptions which may not be universally applicable. For example, when using a model
which distinguishes the lung into different compartments and using that model to fit to PK
data from COPD patients, the assumption that mucociliary clearance is faster from central
lung may not hold true because of the impaired mucociliary clearance in such patients.
Development of a compartmental PK model to describe this complex lung
disposition PK requires use of assumptions based on knowledge like different lung
absorption rates due to physiological characteristics of the lung, parameters to describe
different absorptive and non-absorptive routes that the drug may take after deposition, as
well as formulation based assumptions, and therefore, a compromise between simplicity
and realism is necessary in modeling approaches, depending on the specific goal of the
modeling approach. (Borghardt et al. 2015) When the goal of the modeling approach is
to understand how disposition kinetics are inhaler- and drug-dependent, it may be feasible
to regard the lung as a single compartment in the model to simplify the model and
decrease the number of parameters in the model that need to be derived, thereby
preventing overparameterization of the model. An example of a complex PK model was
published by Miller et al. (2010) which was developed with the goal to predict budesonide
inhaled drug PK profile. It was observed that the model prediction of the Cmax and Tmax of
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the budesonide inhaled PK profile were slightly deviated from the literature budesonide
inhaled PK profile. This may be because the model described the lungs as a collection of
up to five compartments (nose, extra-thoracic, thoracic, bronchiolar and alveolar). The
lung disposition was assumed to be controlled by dissolution, absorption into pulmonary
cells and eventually into systemic circulation, mucociliary clearance and metabolism with
a parameter included in the model for each process; while also accounting for fractions
of unbound drug in the mucus/surfactant layers and the pulmonary cells. In addition, the
model also used literature values to describe human lung physiological parameters
(surface area, thickness and volume for the mucus and cell) for each of the five lung
compartments, pulmonary permeability and systemic PK parameters. Thus, these large
number of parameters in the model could have overparameterized the model, causing
some deviations in the observed budesonide PK profile and the predicted profile.

Another example of the modeling approach was published by Weber and
Hochhaus (2013) where the PK parameter estimates were derived from the literature to
describe the systemic PK profiles of inhaled drugs. The PK parameters that were
unavailable in the literature were assigned with assumptions for characteristics of
absorption rate constants and pulmonary deposition patterns. The authors also assumed
the fraction of the dose deposited in the mouth-throat to be swallowed and absorbed from
the GI tract to contribute to the systemic drug levels, when appropriate. Notably, the drug
dose deposited in the lung was differentiated into two kinetically different absorption, by
modeling different rates of absorption from two lung compartments, the central and
peripheral lungs. In addition, the rate estimates for mucociliary clearance and dissolution
were obtained from the literature and included in the PK model. Simulations were
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performed with this PK model, which were found to be well compared with the PK results
of four clinical studies. Thus, by comparing this model to the previous example published
by Miller et al., it may be speculated that a simpler model with less number of parameters
allowed prediction of PK profiles more consistent with the literature PK profiles. However,
the impactor data was used as the total and regional lung deposited doses, which would
require caution, because as described previously, such in vitro data may not accurately
represent drug dose to lung due to poor sensitivity and predictive capability of in vitro data
to in vivo performance.
Subsequently, Sakagami (2014) employed another kinetic model which
incorporated a fraction of the dose deposited in the lung as well as regional lung
deposition in the central and peripheral lungs, in addition to dissolution rate-controlled
lung absorption and mucociliary clearance from both the central and peripheral lung to
analyze clinical PK profiles from the literature for inhaled fluticasone propionate and
fluticasone furoate. In the model, the systemic PK parameters and mucociliary clearance
kinetics were fixed at their literature values. The model fitting was found to be successful
in explaining and predicting the PK profiles for both inhaled drugs. However, the total and
regional lung deposition fractions were derived from impactor data, which may not
accurately predict in vivo deposition. This model distinguished the lung into two
compartments, while assuming that the dissolution controlled-rate of absorption of
fluticasone was unaltered in these two lung regions. Thus it remains to be seen how the
prediction accuracy of the model would change in this case by including the lung as a
single compartment in the model, thereby allowing a decrease of the number of
parameters in the model.
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The lung disposition kinetics is complex and confounded by many variables like
lung delivery and deposition, dissolution in the LLF, absorption and several other
clearance processes such as mucociliary clearance, metabolism, phagocytosis and
tissue binding. However, it is desirable to minimize this complexity using a simpler lung
deposition and disposition-based compartmental PK model which allows a compromise
between simplicity and realism, so that accurate derivation and prediction of key
parameters determining the inhaled PK profiles may become feasible. In pursuit of this
goal, this thesis research describes use of a simpler lung deposition and disposition PK
model to derive the lung disposition kinetic descriptors of three drug molecules using
curve fitting- and moment analysis-based approaches. Simulation was then performed to
assess the effects of changes in lung delivery and disposition parameters on the systemic
PK and local lung exposure profiles.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS

This thesis project aims to apply the lung disposition model-based analysis to the
inhaled pharmacokinetic (PK) profile data for three drugs in humans to derive accurate
kinetic descriptors (rate constants) for lung disposition with negligible GI absorption. It is
hypothesized that their lung disposition kinetics can be described with absorption (ka) and
non-absorptive loss (knal), derived from the inhaled PK profiles and corresponding scintigraphic lung deposition data by using curve fitting-based and moment-based
approaches. By so doing, such kinetic descriptors of lung disposition can be identified
and discussed as drug-, inhaler- and lung deposition-dependent values. Moreover,
inhaled PK profile prediction by simulation enables identification of the impact of
change/difference/variance of each attribute. The project is designed to pursue the
following five specific aims:
1. Identify drugs with available necessary data sets (i.e., inhaled PK profiles and
corresponding -scintigraphic lung deposition data alongside intravenous PK profiles)
by performing an exhaustive literature review
2. Develop a lung deposition and disposition-based compartment model for inhaled PK
profile analysis using curve fitting-based and moment-based approaches
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3. Derive the kinetic descriptors of lung absorption and non-absorptive loss (ka and knal,
respectively) for three drugs through curve fitting-based approach
4. Derive the kinetic descriptors of lung absorption and non-absorptive loss (ka and knal,
respectively) for three drugs through moment-based approach
5. Predict changes in the inhaled PK profiles and their parameter metrics in response to
±20 % change/difference/variance of each attribute by simulation
In Chapter 3, upon literature selection of three drugs, i.e., tobramycin, calcitonin
and ciprofloxacin, their inhaled PK profiles will be analyzed using curve fitting-based
approach to derive drug-, inhaler- and/or lung deposition-dependent ka and knal values. In
Chapter 4, the identical inhaled PK and lung deposition data sets will be analyzed using
moment-based approach to derive and compare the ka and knal values. In Chapter 5,
inhaled PK and lung exposure profiles will be predicted by simulation in response to ±20
% change/difference/variance of each attribute from the reference standard condition.
Finally, Chapter 6 will summarize all the findings in this thesis project and provide overall
conclusions.
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CHAPTER 3
LUNG DISPOSITION KINETIC ANALYSIS VIA CURVE FITTING APPROACH

3.1

Introduction
As described in Chapter 1, lung disposition kinetics of inhaled drugs is complex

and thus its accurate understanding is challenging. 1) Only a portion of the formulated
drugs is deposited in the lung, which is rarely determined; 2) lung-deposited drugs are
absorbed from the lung, but absorption may also occur, when drugs are swallowed and
reach the gastrointestinal (GI) tract; and 3) lung delivery and regional deposition depend
on formulation and inhaler, which may cause different pharmacokinetic (PK) profiles
(Hochhaus 2007). Even so, more accurate understanding of the inhaler- and lung
deposition-dependent kinetic behavior is desired to aid successful inhaled drug and
product development for local and systemic use in patients.
Nonlinear regression curve fitting can be a powerful approach to derive kinetic
descriptors for such multi-complex deposition and disposition kinetics in the lungs for
inhaled drugs from the PK profile data. In this chapter, the literature was searched and
three drugs tested for inhalation, tobramycin, calcitonin and ciprofloxacin, were chosen,
based on availability of all necessary data sets: a) dose deposited in the lung (DTL) by -
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scintigraphy; b) intravenous injection/infusion (IV) profile data; and c) inhaled PK profile
data. Hence, the lung deposition and disposition were kinetically modeled along with the
systemic disposition and used for curve fitting the PK profiles to derive the lung disposition
kinetic descriptors, the rate constants of absorption (ka) and non-absorptive loss (knal)
using Scientist® 3.0 (MicroMath, Saint Louis, MO).

3.2

Methods

3.2.1 Literature data collection
An exhaustive literature search was conducted in PubMed and Google Scholar to
identify the following data sets for drugs in healthy subjects for use in this curve fittingbased lung disposition kinetic analysis: 1) PK profile and -scintigraphy lung deposition
data following inhalation with the same inhaler device; 2) lack of GI absorption and 3) PK
profile data following IV injection/infusion. The search terms used in PubMed and Google
Scholar were “inhalation PK profile with lung deposition by -scintigraphy in healthy
volunteers” for inhaled PK profiles alongside corresponding inhaler’s dose delivered to
lung. Following identification of drug molecules with such available data sets for inhaled
PK, the search term “IV PK profile healthy volunteers” for the corresponding drug
molecule was used to identify IV PK profiles. Following identification of all necessary data
sets, the study design and details, e.g., the number and demographics of healthy
subjects, dose and plasma/serum concentration, sampling time interval and duration,
drug assay method and validation, were also carefully inspected to be consistent or
comparable across the studies. As a result, tobramycin, calcitonin and ciprofloxacin were
chosen for use in this study, and their mean plasma/serum concentration vs. time profile
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data for IV and inhaled administration were extracted using GetData Graph Digitizer, a
program to digitize graphs and plots (http://getdatagraphdigitizer.com). Notably, these
three drugs differ with respect to their physicochemical properties and the absence
(tobramycin and calcitonin) or presence (ciprofloxacin) of GI absorption, as shown in
Table 3.1.

Table 3.1. Physicochemical properties and absence/presence of GI absorption of
tobramycin, calcitonin and ciprofloxacin.
Drug
MW (Da)
Log KD
Aqueous solubility
(mg/ml)
Oral bioavailability
(%)

Tobramycin
468
-10
>50

Calcitonin
3,432
-33
1

<1 due to low
permeability

<1 due to
proteolytic
degradation
Inhaler device
DPI, NEB
DPI, NEB
KD: Distribution coefficient, DPI: Dry powder inhaler, NEB: Nebulizer

Ciprofloxacin
331
-2
0.08
70

DPI

3.2.2 Estimation of systemic PK parameters
Systemic PK parameters were estimated from the IV PK profile data first by the
method of residuals, followed by nonlinear regression curve fitting using Scientist® 3.0
(MicroMath, Saint Louis, MO). The parameter values derived by method of residuals were
used as initial estimates to derive the best estimates using curve fitting. Method of
residuals employs linear regression of the α- and β-phases of the PK profiles which allows
derivation of a single value as the parameter estimate. However, curve fitting employs
nonlinear regression for curve fitting which derives the “best” estimate by reaching the
global minimum value as the parameter estimate. Thus, nonlinear regression curve fitting
was employed to more accurately derive PK parameter estimates. The one- or two20

compartment open body model shown in Figure 3.1 or 3.2, respectively, was used
depending on the mono- or bi-exponential decline in the PK profiles. The PK profiles that
follow the one-compartment model (Figure 3.1) were generally described by:
dMC/dt = k0 - k10 * MC

Equation 3.1

where MC is the drug mass in the central compartment; k0 is the zero-order infusion rate
for IV infusion during the infusion period and otherwise, 0 for IV bolus injection or IV
infusion after the infusion period; and k10 is the first-order elimination rate constant from
the central compartment. In contrast, the PK profiles that follow the two-compartment
model (Figure 3.2) were described by:
dMC/dt = k0 + k21 * MP - (k12+k10) * MC

Equation 3.2

where MP is the drug mass in the peripheral compartment; k12 and k21: the first-order rate
constants for transfer from the central to the peripheral compartment and from the
peripheral to the central compartment, respectively; and k0 is as described previously.
The IV PK profiles were first analyzed using the method of residuals as described
in Gibaldi & Perrier (1982) to estimate the rate constant and VC values for use as the
initial estimates in the subsequent curve fitting. With these initial estimates, the nonlinear
regression curve fitting was performed using Scientist to more accurately derive each of
the rate constant and VC values. The goodness-of-fit of the curve fitting was assessed
with the 95% confidence intervals (CI) for the derived estimates, Scientist-derived
coefficient of determination (COD) and model selection criterion (MSC), and visual
inspection of residuals in the PK profiles.
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IV bolus or infusion

MC

VC

Central
compartment

k10

Figure 3.1. One-compartment open body model: k10; first-order rate constant for

elimination; and VC: apparent volume of distribution of the central compartment.

IV bolus or infusion

VC

MC

Central
compartment

k12

MP
Peripheral
compartment

k21
k10

Figure 3.2 Two-compartment open body model: k10, k12 and k21: the first-order rate

constants for elimination from the central compartment, transfer from the central to the
peripheral compartment, and transfer from the peripheral to the central compartment,
respectively; and VC: apparent volume of distribution of the central compartment.
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3.2.3 Curve fitting-based estimation of lung disposition kinetic parameters
Each of the inhaled PK profile data was then curve-fitted to the lung deposition and
disposition model shown in Figure 3.3. Note that the systemic disposition model was
either of the one or two-compartment model shown in Figure 3.1 or 3.2, respectively. The
kinetics of lung disposition were assumed to be controlled with the first-order rate
constants of absorption (ka) and non-absorptive loss (knal), which was described by:
dML/dt = -(ka+knal) * ML

Equation 3.3

Upon inhaled administration (t=0), lung deposition, ML,0 was equaled to DTL. Hence, the
systemic compartment disposition was kinetically controlled not only by distribution and
elimination but also by the input rate of ka*ML, i.e., lung absorption.
In this lung disposition PK model, the DTL was obtained from the -scintigraphy
data for each drug dosed with the inhaler in the subjects, consistent with those used to
obtain the inhaled PK profile data. The systemic disposition PK parameters were fixed at
the values obtained by curve fitting the IV PK profile data described above in 3.2.2. Hence,
all the parameters except ka and knal were fixed, and the inhaled PK profile data were
fitted to the model using Scientist to derive the best parameter estimates for ka and knal.
The goodness-of-fit of the curve-fitting was assessed with the 95% CIs for the derived
best parameter estimates, Scientist-derived COD and MSC, and visual inspection of
residuals in the PK profiles.
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DTL

Lung

knal

ka

Systemic disposition

Elimination

Figure 3.3 The lung deposition and disposition model incorporating absorption and
non-absorptive loss, along with the systemic elimination. The lung receives dose-tothe lung (DTL) upon inhaled administration. Lung’s absorption and non-absorptive loss
are kinetically described with the first-order rate constants, ka and knal, respectively.
The systemic disposition follows either one- or two-compartment model described in
Figure 3.1 and 3.2, respectively. Hence, the systemic disposition kinetics were
controlled not only by elimination and distribution but also by lung absorption as an
input function.
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3.3

Results and Discussion

3.3.1 Literature data collection
By employing the search terms “inhalation PK profile with lung deposition by scintigraphy in healthy volunteers” in PubMed and Google Scholar, research papers were
identified for albuterol, budesonide, calcitonin, ciprofloxacin and tobramycin. After a
thorough review of the five identified research papers, it was observed that inhaled PK
study of albuterol (Hirst et al. 2002) reported only the -scintigraphy lung dose without the
corresponding inhaled PK profile in healthy volunteers. In case of budesonide, the
identified inhaled PK study (Thorsson et al. 1994) reported only the inhaled PK profile
without GI absorption without the corresponding -scintigraph lung dose. On the contrary,
in case of tobramycin, calcitonin and ciprofloxacin, both necessary data sets of inhaled
PK profile without GI absorption and corresponding -scintigraphy lung deposition data
following inhalation with the same inhaler device were identified. Therefore, intravenous
injection/infusion (IV) PK profile literature data search was conducted only for tobramycin,
calcitonin and ciprofloxacin and albuterol and budesonide were eliminated from the list of
drug molecules eligible for this project on account of unavailability of all necessary data
sets.

3.3.2 Tobramycin
The IV PK profile data were taken from Pleasants et al. (1988) which employed
0.5 h infusion at a dose of 1.5 mg/kg. The -scintigraphic DTL and inhaled PK data were
taken from Newhouse et al. (2003), obtained following 0.25 h inhaled administration of
spray-dried powders from Turbospin DPI (DPI) and solution aerosols from PARI LC Plus
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Nebulizer (NEB). The study design and details are summarized in Table 3.2, which was
considered comparable. The IV and inhaled PK profiles are shown in Figure 3.4 and 3.5,
respectively, while the -scintigraphic data are shown in Table 3.3. Given the linear PK
assumption of the lung deposition and disposition PK model, literature IV and inhaled PK
data were assessed for dose proportionality. Literature reported IV dose (Pleasants et al.)
and DTL (Newhouse et al.) for DPI and NEB were assessed for linearity with the
corresponding literature reported area under the serum concentration vs. time curve
(AUC) and it was observed that AUC showed dose linearity. Hence it was assumed that
tobramycin followed linear PK at the reported IV dose and DTL for both inhalers.

Table 3.2 Study design and drug assay method for the studies used in the curve fittingbased lung disposition kinetic analysis for tobramycin.
Literature

IV PK
Pleasants et al.

Subject (N)
Gender (M/F)
Race
Age (years)*
Weight (kg)*

12
12/0
NR
26 ± 3
78.8 ± 11.4

DTL and inhaled PK
Newhouse et al.
DPI
NEB
12
10/4
NR
34 ± 8
NR

Formulation dose
Infusion time (h)

1.5 mg/kg
0.5

80 mg
NA

Sampling points (h)

300 mg
NA

0.17, 0.33, 0.50, 0.67,
0, 0.25, 0.50, 1.00, 1.50, 2.00, 3.00,
0.83, 1.00, 1.33, 1.50,
4.00, 6.00, 8.00
1.67, 2.00, 2.50, 3.00,
4.00, 6.00, 8.00
Assay method
Fluorescence
Fluorescence polarization
polarization
immunoassay
immunoassay
LLOQa (mg/L)
0.18
0.05
*Mean ± SD; aLower limit of quantitation; NR: Not reported; and NA: Not applicable
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Figure 3.4 Mean serum tobramycin concentration vs. time following 0.5 h IV infusion
at a dose of 1.5 mg/kg. Data were taken from Pleasants et al., (1988).
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Figure 3.5 Mean (± SD) serum tobramycin concentration vs. time following inhaled DPI
and NEB administration. Data were taken from Newhouse et al. (2003).
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Table 3.3 % tobramycin deposition following inhaled DPI and NEB administration,
measured by -scintigraphy. Data were taken from Newhouse et al. (2003).
Device
DPI
NEB
DPI capsule
13.3 ± 4.2
NA
Turbospin inhaler
8.4 ± 1.0
NA
Nebulizer cup
NA
55.7 ± 5.6
Nebulizer mouthpiece and NA
4.9 ± 2.2
T-piece
Exhalation filter
0.20 ± 0.10
26.4 ± 3.2
Emitted dose
78.3 ± 10.3
39.4 ± 5.1
Oropharynx,
esophagus 43.6 ± 8.6
8.2 ± 3.6
and stomach
DTL
34.3 ± 5.8
5.0 ± 2.0
P/C ratio
1.6 ± 0.4
1.5 ± 0.4
Data: Mean ± SD; NA: Not applicable; P/C ratio: Peripheral-to-central deposition ratio
It should be noted that DPI and NEB employed substantially different doses (80
and 300 mg, respectively; Table 3.2), as well as differences in % emitted dose (78.3 and
39.4%; Table 3.3) and % DTL (34.3 and 5%; Table 3.3) were reported. As a result, the
DTL calculated from the formulation dose and % DTL were 27.4 mg for DPI and 15.0 mg
for NEB. That is, the DTL for DPI was almost twice of that for NEB in this study.
With the IV profile data shown in Figure 3.4, the initial estimates for the systemic
two-compartment model disposition parameters obtained by the method of residuals are
shown in Table 3.4. Curve-fitting was then performed with Scientist, which was
successful, given 0.99 of COD and 4.2 of MSC as well as small residuals seen in profiles,
as shown in Figure 3.6. As a result, the best parameter estimates were derived in a more
accurate manner, as also shown in Table 3.4. It was observed that method of residuals
derived rate constants k10, k12 and k21 were bracketed by the 95% CI of those derived by
curve fitting. However, method of residuals appeared to underestimate the V C, which may
have been because method of residuals does not allow accounting for the time of infusion,
28

which was incorporated in curve fitting based estimation of the parameters, thereby
allowing an accurate estimation of the parameters.

Table 3.4 Values of the initial estimates obtained by the method of residuals and the
best estimates derived by the curve fitting for the two-compartment model parameters
of tobramycin from the IV PK profile data.

Serum concentration (mg/L)

Systemic PK parameter
k10 (h-1)
(95% CI)
k12 (h-1)
(95% CI)
k21 (h-1)
(95% CI)
VC (L)
(95% CI)

Initial estimate
0.63
0.50
0.83
8.27

Best estimate
0.53
(0.41, 0.65)
0.36
(0.14, 0.58)
0.69
(0.09, 1.48)
11.4
(10.5, 12.3)
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Figure 3.6 The model-predicted profile of the serum concentration of tobramycin vs.
time following IV infusion. Data were taken from Pleasants et al. The dashed line is the
model-predicted profile generated using the best parameter estimates shown in Table
3.4.

The inhaled PK profile data for DPI and NEB shown in Figure 3.5 were each curvefitted to the kinetic model shown in Figure 3.3. The DTL was fixed at 27.4 mg for DPI and
29

15.0 mg for NEB, as estimated from the -scintigraphic data (i.e., the formulation dose x
% DTL). The systemic disposition parameters were also fixed with the values derived
from the IV PK profile data, as shown above. While these were fixed, the lung disposition
kinetic parameters, ka and knal, were floated in curve fitting with Scientist to be derived
from each of the inhaled PK profiles of Newhouse et al. The derived k a and knal values
are shown in Table 3.5, along with the goodness-of-fit parameters, COD and MSC. In
Figure 3.7, only small deviations are shown between the data and the prediction,
demonstrating sufficient curve-fitting, despite slightly lower MSC and COD values (Table
3.5). The lower COD and MSC values may be because the number of data points before
the maximum serum concentration (Cmax) after inhalation from both DPI and NEB were
only 3, with a total of 9 data points in the sampling duration of 8 h. Such limited number
of data points penalizes the MSC and COD values due to overparameterization of the
model, which relies on the total number of data points as well as the data points around
the higher concentrations available for curve fitting to derive the ka and knal values.

Table 3.5 The best parameter estimates for the ka and knal values of tobramycin derived
through curve-fitting of the inhaled PK profile data reported in Newhouse et al, along
with the Scientist-derived goodness-of-fit parameters, COD and MSC.
ka (h-1)
knal (h-1)
(95% CI)
(95% CI)
DPI
0.45
0.08
(0.35, 0.55)
(0.02, 0.17)
NEB
0.34
0.08
(0.28, 0.40)
(0.01, 0.15)
*Coefficient of determination; +Model selection criteria
Device
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Figure 3.7 The model-predicted profiles of the serum concentration of tobramycin vs.
time following inhaled DPI and NEB administration. Data were taken from Newhouse
et al. The dashed lines are the model-predicted profiles generated using the best
parameter estimates shown in Table 3.5.

3.3.3 Calcitonin
The IV PK profile data were taken from Buclin et al. (2002), which employed 1 h
infusion at a dose of 10 µg. The -scintigraphic DTL and inhaled PK data were taken from
Clark et al. (2008), obtained following inhaled administration of spray-dried powders from
Nektar pulmonary delivery system (DPI) and 0.04 h inhalation of solution aerosols from
Salter nebulizer (NEB). The study design and details are summarized in Table 3.6, which
was considered comparable. The IV and inhaled PK profiles are shown in Figure 3.8 and
3.9, respectively, while the -scintigraphic data are shown in Table 3.7. Both the IV and
inhaled PK studies employed immunoassay based techniques to measure calcitonin
concentrations after IV and inhaled administration. Given the issues of cross-reactivity
based interference with immunoassay techniques, and since the inhaled PK study in
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Clark et al. did not comment on the specificity of the radioimmunoassay technique used
alongside possible metabolite cross-reactivity, it was assumed that the reported plasma
concentrations after IV and inhaled administration were accurate, until further information
on cross-reactivity is available through literature for that specific radioimmunoassay
technique used in Clark et al. Given the linear PK assumption of the lung deposition and
disposition PK model, literature IV and inhaled PK data were assessed for dose
proportionality. Literature reported IV dose (Buclin et al.) and DTL (Clark et al.) for DPI
and NEB were assessed for linearity with the corresponding literature reported area under
the serum concentration vs. time curve (AUC) and it was observed that AUC showed
dose linearity. Hence it was assumed that calcitonin followed linear PK at the reported IV
dose and DTL for both inhalers.

Table 3.6 Study design and drug assay method for the studies used in the curve fitting
-based lung disposition kinetic analysis for calcitonin.
Literature

IV PK
Buclin et al.

Subject (N)
Gender (M/F)
Race
Age (years)
Weight (kg)*

8
8/0
NR
22-37*
65-86

DTL and inhaled PK
Clark et al.
DPI
NEB
16
8/8
NR
32+
NR

Formulation dose
Infusion time (h)

10 µg
1

300 µg
NA

Sampling points (h)

NR
NA

0, 0.25, 0.50, 0.76, 1.00, 0, 0.08, 0.17, 0.33, 0.5, 1, 2, 4, 6
1.50, 2.00
Assay method
ChemoluminescenceRadioimmunoassay
based
sandwich
immunoassay
LLOQa (pg/ml)
2.5
NR
*Range; +Mean; aLower limit of quantitation; NR: Not reported; and NA: Not applicable
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Figure 3.8 Mean (± SD) plasma calcitonin concentration vs. time following 1 h IV
infusion at a dose of 10 µg. Data were taken from Buclin et al. (2002).
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Figure 3.9 Mean (± SD) plasma calcitonin concentration vs. time following inhaled DPI
and NEB administration. Data were taken from Clark et al. (2008).
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Table 3.7 Calcitonin deposition (µg) following inhaled DPI and NEB administration,
measured by -scintigraphy. Data were taken from Clark et al. (2008).
Device
DPI
NEB
DTL (µg)
52.9 ± 12.8
56.9 ± 9.00
P/C ratio
0.8 ± 0.3
1.4 ± 0.3
Data: Mean ± SD; P/C ratio: Peripheral-to-central deposition ratio
It should be noted that DPI employed 300 µg of the formulation dose, while the
dose formulated in NEB was not reported (Table 3.6). The DTL was reported 52.9 µg for
DPI and 56.9 µg for NEB. That is, the DTL was comparable between DPI and NEB
administration in this study (Table 3.7).
With the IV profile data shown in Figure 3.8, the initial estimates for the systemic
one-compartment model disposition parameters were obtained, as shown in Table 3.8.
Curve fitting was then performed with Scientist, yielding 0.95 of COD and 2.46 of MSC.
As shown In Figure 3.10, small deviations were seen between the actual and modelpredicted profiles, demonstrating sufficient curve-fitting. As a result, the best parameter
estimates were derived in a more accurate manner, as shown in Table 3.8. It was
observed that the k10 and VC derived by method of residuals were bracketed by 95% CI
of those derived by curve fitting, however it is believed that curve fitting allows a more
accurate estimation of parameters because as described previously, curve fitting employs
nonlinear regression which allows derivation of the “best” estimate while reaching the
global minimum.
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Table 3.8 Values of the initial estimates obtained by the method of residuals and the
best estimates derived by the curve fitting for the one-compartment model parameters
of calcitonin from the IV PK profile data.
Systemic PK parameter
k10 (h-1)
(95% CI)
VC (L)
(95% CI)

Initial estimate
3.77
15.0

Best estimate
3.72
(1.24, 6.21)
17.9
(8.24, 27.6)
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Figure 3.10 The model-predicted profile of the plasma concentration of calcitonin vs.
time following IV infusion. Data were taken from Buclin et al. The dashed line is the
model-predicted profile generated using the best parameter estimates shown in Table
3.8.

The inhaled PK profile data for DPI and NEB shown in Figure 3.9 were each curvefitted to the kinetic model shown in Figure 3.3. The DTL was fixed at 52.9 µg for DPI and
56.9 µg for NEB, as reported by -scintigraphy. The systemic disposition parameters were
also fixed with the values derived from the IV PK profile data, as shown above. While
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these were fixed, the lung disposition kinetic parameters, ka and knal, were floated in curve
fitting with Scientist to be derived from each of the inhaled PK profiles of Clark et al. The
derived ka and knal values are shown in Table 3.9, along with the goodness-of-fit
parameters, COD and MSC. In Figure 3.11, only small deviations are shown between the
actual data and the model-predicted profiles, demonstrating sufficient curve fitting,
despite slightly lower MSC and COD values (Table 3.9). The lower COD and MSC values
may be because the number of data points before the maximum plasma concentration
(Cmax) after inhalation from DPI was just 1, and that after inhalation from NEB were only
3, with a total of 7 data points in the sampling duration of 6 h for both devices. Such limited
number of data points penalizes the MSC and COD values due to overparameterization
of the model, which relies on the total number of data points as well as the data points
around the higher concentrations available for curve fitting to derive the k a and knal values.

Table 3.9 The best parameter estimates for the ka and knal values of calcitonin derived
through curve fitting of the inhaled PK profile data reported in Clark et al, along with the
Scientist-derived goodness-of-fit parameters, COD and MSC.
ka (h-1)
knal (h-1)
(95% CI)
(95% CI)
DPI
0.06
2.32
(0.04, 0.07)
(1.24, 3.40)
NEB
0.05
1.22
(0.04, 0.06)
(0.84, 1.61)
*Coefficient of determination; +Model selection criteria
Device
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Figure 3.11 The model-predicted profiles of the plasma concentration of calcitonin vs.
time following inhaled DPI and NEB administration. Data were taken from Clark et al.
The dashed lines are the model-predicted profiles generated using the best parameter
estimates shown in Table 3.9.

3.3.4 Ciprofloxacin
The IV PK profile data were taken from Brunner et al. (1999) which employed 0.17
h infusion at a dose of 200 mg. The -scintigraphic DTL and inhaled PK data were taken
from Stass et al. (2016) obtained following inhaled administration of spray-dried powders
from Novartis T-326 inhaler (DPI). The subjects received charcoal orally to block
gastrointestinal (GI) absorption of ciprofloxacin deposited in the oropharynx and
swallowed to the GI tract. The study design and details are summarized in Table 3.10,
which was considered comparable. The IV and inhaled PK profiles are shown in Figure
3.12 and 3.13, respectively, while the -scintigraphic data are shown in Table 3.11. Given
the linear PK assumption of the lung deposition and disposition PK model, literature IV
and inhaled PK data were assessed for dose proportionality. Literature reported IV dose
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(Brunner et al.) and DTL (Stass et al.) for DPI were assessed for linearity with the
corresponding literature reported area under the serum and plasma concentration vs.
time curve (AUC) and it was observed that AUC showed dose linearity. Hence it was
assumed that ciprofloxacin followed linear PK at the reported IV dose and DTL for DPI.

Table 3.10 Study design and drug assay method for the studies used in the curve
fitting-based lung disposition kinetic analysis for ciprofloxacin.
Literature

IV PK
Brunner et al.

Subject (N)
Gender (M/F)
Race
Age (years)*
Weight (kg)+

8
8/0
NR
28-37
76 ± 4

DTL and inhaled PK
Stass et al.
DPI
12
12/0
NR
21-52
NR

Formulation dose
Infusion time (h)

200 mg
0.17

32.5 mg
NA

Sampling points (h)

0.33, 0.67, 1.00, 1.33, 1.67, 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8
2.00, 2.33, 2.67, 3.00, 3.33,
3.67, 4.00, 4.33, 4.67, 5.00,
5.33, 5.67, 6.00, 6.33, 6.67,
7.00, 7.33, 7.67, 8.00
Assay method
High
performance
liquid Chromatography with mass
chromatography
with spectrometry
fluorometric detection
LLOQa (mg/L)
0.05
NR
*Range; +Mean ± SE; aLower limit of quantitation; NR: Not reported; and NA: Not
applicable
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Figure 3.12 Mean (± SE) serum ciprofloxacin concentration vs. time following 0.17 h
IV infusion at a dose of 200 mg. Data were taken from Brunner et al. (1999).
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Figure 3.13 Mean (± SD) plasma ciprofloxacin concentration vs. time following inhaled
DPI administration. Data were taken from Stass et al. (2016).
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Table 3.11 % Ciprofloxacin deposition following DPI administration, measured by scintigraphy. Data were taken from Stass et al. (2016).
Inhaler
4±1
Exhaled
1
Extra-thoracic region
44 ± 8
DTL
51 ± 7
P/C ratio
0.6
Data: Mean ± SD; P/C ratio: Peripheral-to-central deposition ratio
Note that the DPI formulation dose was 32.5 mg (Table 3.10) and % DTL was 51%
(Table 3.11), thereby estimating 16.58 mg of the DTL.
The initial estimates for the systemic disposition two-compartment model
disposition parameters were estimated by the method of residuals on the IV PK profile
reported in Brunner et al., as summarized in Table 3.12. The IV PK profile was then fitted
to the two-compartment model with the initial estimates (Table 3.12) for a more accurate
determination. The best estimates were derived as shown in Table 3.12. The fitted profile
provided a good fit of the data as shown in Figure 3.14, and the COD was 0.99 and the
MSC was 4.88. It was observed that k10 and VC derived by method of residuals were
bracketed by the 95% CI of those derived by curve fitting, whereas k 12 and k21 values
derived by method of residuals were smaller than the lower level of the 95% CI of those
derived by curve fitting. However, curve fitting derived values of parameters were
assumed to be more accurate, as described previously.
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Table 3.12 Values of the initial estimates obtained by the method of residuals and the
best estimates derived by the curve fitting for the two-compartment model parameters
of ciprofloxacin from the IV PK profile data.

Serum concentration (mg/L)

Systemic PK parameter
k10 (h-1)
(95% CI)
k12 (h-1)
(95% CI)
k21 (h-1)
(95% CI)
VC (L)
(95% CI)

Initial estimate
0.58
1.02
0.64
95.4

Best estimate
0.64
(0.57, 0.72)
1.42
(1.11, 1.73)
0.86
(0.70, 1.03)
93.2
(84.4, 100)
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Figure 3.14 The model-predicted profile of the serum concentration of ciprofloxacin
vs. time following IV infusion. Data were taken from Brunner et al. The dashed line is
the model-predicted profile generated using the best parameter estimates shown in
Table 3.12.
The lung disposition kinetic parameters, ka and knal, were derived by curve fitting
the inhaled PK profiles of ciprofloxacin for DPI reported in Stass et al. The PK profile data
was fitted to the lung disposition PK model shown in Figure 3.3, with the systemic
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disposition kinetic parameters fixed as described by the two-compartment model (Table
3.12). The scintigraphic DTL was also fixed as shown in Table 3.11. The ka and knal
values derived for DPI are shown in Table 3.13 along with 95% CI and goodness of fit
statistics. The curve fitting provided a good fit of the data with the lung disposition model
with the systemic PK described by the two-compartment model. The COD and MSC were
slightly lower, while only small deviations were seen between the data and the modelpredicted profile (Figure 3.15). The lower COD and MSC values may be because there
were no data points before the maximum plasma concentration after inhalation from DPI,
with a total of 9 data points in the sampling duration of 8 h. Such limited number of data
points penalizes the MSC and COD values due to overparameterization of the model,
which relies on the total number of data points as well as the data points around the higher
concentrations available for curve fitting to derive the ka and knal values.

Table 3.13 The best parameter estimates of the k a and knal values of ciprofloxacin
derived through curve fitting of PK profile data reported in Stass et al along with the
Scientist-derived goodness of fit parameters, COD and MSC.
ka (h-1)
knal (h-1)
(95% CI)
(95% CI)
DPI
0.98
0.61
(0.71, 1.25)
(0.36, 0.86)
*Coefficient of determination; +Model selection criteria
Device
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Figure 3.15 The model-predicted profiles of the plasma concentration of ciprofloxacin
vs. time following inhaled DPI administration. Data were taken from Stass et al. The
dashed lines are the model-predicted profiles generated using the best parameter
3.3.5
estimates shown in Table 3.13.

3.3.5 The ka and knal values across three molecules
Curve fitting approach was successfully used, yielding sufficient “goodness-of-fit”
statistical parameters and deriving the ka and knal values for all the three molecules with
small 95% CI. The curve fitting approach employed compartment model-based differential
equations for non-linear regression of the literature PK profile data for IV and inhaled
administration. The DTL and systemic PK parameters were fixed and only the ka and knal
were allowed to float.
The IV PK profile of tobramycin in healthy volunteers was also found in Haughey
et al. (1980) and Péchère et al. (1976). However, Pleasants et al. (1988) was chosen,
because most frequent sampling over a sufficient length of time (8 h) was taken, and the
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assay method was reliable and same as that used in Newhouse et al. (2003). Haughey
et al. and Péchère et al. both used a microbiological assay. Besides, Haughey at al.
(1980) reported the PK profile from just one volunteer. The inhaled PK profiles of
tobramycin were also found in Pilcer et al. (2008), but in cystic fibrosis (CF) patients.
Given the pathophysiology of CF lungs, inhaled drug disposition kinetics were likely
affected by the disease condition. For calcitonin and ciprofloxacin, an exhaustive literature
search could not find other IV or inhaled PK profiles in healthy volunteers or the
corresponding -scintigraphy-based lung deposition data.
Byron and Patton (1994) proposed the following equation with an assumption that
lung absorption undergoes passive diffusion via partitioning through cell membranes:
ka= DM*AM*KD/(h*VLLF)

Equation 3.4

where DM is the diffusion coefficient through lung membrane, AM is the total lung
membrane surface area, KD is the drug partition/distribution coefficient, h is the thickness
of lung membrane and VLLF is the lung lining fluid (LLF) volume. Assuming the
physiological parameters AM, h and VLLF as constant, ka now becomes dependent on
DM*KD and given that DM is proportional to 1/(MW)1/3 as per the Stokes-Einstein equation,
ka is now dependent on KD/(MW)1/3. Therefore, the derived ka values were plotted against
the respective KD/(MW)1/3, yielding equation log [ka] = 0.05 + 0.04 x log [KD/(MW)1/3] (R2=
0.99) which found a good correlation, as shown in Figure 3.16-A. However, given the loglog plot, the equation implies that ka is proportional to KD/(MW)1/3 only when it is raised to
power 0.04 (slope).

44

Figure 3.16-A Correlation between ka and KD/(MW)1/3 for tobramycin, calcitonin and
ciprofloxacin.

Figure 3.16-A implies that ka is not proportional to KD/(MW)1/3 unless it was raised
to a power of 0.04. It may be because all the molecules are hydrophilic in nature with
negative log KD values. Thus, assuming ka to be independent of KD in case of these three
hydrophilic molecules, ka was plotted against 1/(MW)1/3 only, as can be seen in Figure
3.16-B yielding equation log [ka] = 2.6 + 3.0 x log [1/(MW)1/3] (R2= 0.96) which also found
a good correlation. However, given the log-log plot, the equation implies that ka is
proportional to 1/(MW)1/3 only when it is raised to power 3 (slope). This in turn implies that
for tobramycin, calcitonin and ciprofloxacin, ka is proportional to 1/(MW), indicating that
their molecular weight appears to primarily control their absorption kinetics from the lung.
That is, for large hydrophilic calcitonin, the ka value was the smallest, followed by small
hydrophilic tobramycin, and finally, smaller hydrophilic ciprofloxacin. Ciprofloxacin is a
substrate for active transport through bronchial epithelium by OCTs and OATP2B1 (Ong
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et al. 2013), and so even though Figure 3.16-B implies ciprofloxacin absorption kinetics
being primarily controlled by its MW, the derived high ka value may also be confounded
by its active uptake through the central lung, which is consistent with its low P/C ratio of
0.6 indicating its deposition primarily in the central lung.

Figure 3.16-B Correlation between ka and 1/(MW)1/3 for tobramycin, calcitonin and
ciprofloxacin.

The drug’s solubility may also play an important role in its absorption rate, and if
so, their lung absorption kinetics could be dissolution controlled, especially for small
lipophilic molecules like fluticasone propionate (Sakagami 2014). However, the aqueous
solubility values for tobramycin, calcitonin and ciprofloxacin (Table 3.1) are adequately
high and therefore, it is unlikely that their absorption was rate-limited by
solubility/dissolution.
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The ka values also seemed to be dependent on inhaler device as seen for
tobramycin. Different inhalers resulted in different regional lung deposition and
accordingly, different ka values presumably due to different regional lung deposition. It
can be seen that a higher P/C ratio, which indicates a greater fractional deposition in the
peripheral (deeper) lung, produced a greater ka value, in line with our conventional belief
that absorption is faster from the peripheral (deeper) lung by virtue of greater perfusion
and thinner pulmonary membranes.
The knal values for the three drugs were derived in a wide range of 0.08-2.32 h-1,
and seemed to be drug dependent. Byron (1986) and Gonda (1988) reported 0.4-0.7 h-1
as first order rate constant of mucociliary clearance from central lung (kmcc) and 0.17 h-1
as first order rate constant of mucociliary clearance from peripheral lung (kmcp) in humans.
(Sakagami 2004) The knal values for calcitonin were greater than that of kmcc and kmcp
values, perhaps due to local lung metabolism by proteolysis, as similarly suggested for
the knal values for inhaled insulin by Sakagami (2004). On the other hand, the knal values
for tobramycin were smaller than the kmcc and kmcp values, which might be associated with
lung tissue binding of this drug which will be polycationic in nature at physiological pH. Li
and Byron (2013) suggested the lung tissue binding of polycationic tobramycin in the
isolated perfused rat lung (IPRL) at 0.02-100 mg/ml. With 10-30 ml of the lung surface
fluid, 27.4 mg of tobramycin in DTL would result in 0.91–2.74 mg/ml of the lung surface
concentration. Thus, it is possible that tobramycin is highly bound in the lungs. However,
Li and Byron (2003) describe tobramycin’s binding as a biphasic process, involving
sequestration/binding followed by a slow desequestration/dissociation, which implies that
it may be released from the lung tissue in a time-dependent manner, and this released
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fraction will then be available for absorption and non-absorptive clearance pathways
including mucociliary clearance. Thus, caution must be exercised when interpreting the
0.08 h-1 of the derived knal values of tobramycin as caused by tissue binding alone,
because the lung deposition and disposition model (Figure 3.3) does not account for such
time-dependent slow desequestration/dissociation of tobramycin. In that respect, the knal
value for ciprofloxacin was found comparable to the kmcc value, which was consistent with
its lack of local lung metabolism and lung tissue binding.

Table 3.14 Physicochemical properties and the ka and knal values derived by curve
fitting for tobramycin, calcitonin and ciprofloxacin.
Drug
Tobramycin

Calcitonin

Ciprofloxacin

MW
(Da)
468

3,432

331

Log
KD
-10

-33

-2

Inhaler
device
DPI

P/C
ratio
1.6±0.4

NEB

1.5±0.4

DPI

0.8±0.3

NEB

1.4±0.3

DPI

0.6

ka (h-1)
(95% CI)
0.45
(0.35, 0.55)
0.34
(0.28, 0.40)
0.06
(0.04, 0.07)
0.05
(0.04, 0.06)
0.98
(0.71, 1.25)

knal (h-1)
(95% CI)
0.08
(0.02, 0.17)
0.08
(0.01, 0.15)
2.32
(1.24, 3.40)
1.22
(0.84, 1.61)
0.61
(0.36, 0.86)

P/C ratio: Peripheral-to-central deposition ratio

3.4

Conclusions
Using inhaled and IV PK profiles alongside DTL from the lung deposition data in

the literature, the lung disposition kinetic descriptors (ka and knal) in humans were
successfully derived for three drugs delivered by DPI and/or NEB via curve fitting. The ka
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values were found to be dependent on the drug’s MW, as passive diffusion appeared to
be the predominant pathway for these drugs’ absorption. However, regional lung
deposition influenced the ka values in case of tobramycin, and the greater ka value was
seen with higher P/C ratio, i.e., greater deposition in the peripheral lung. While the knal
values did not seem to depend on the physicochemical properties, physiological
processes such as local lung tissue binding, metabolism and mucociliary clearance seem
to affect the knal values. The knal value for ciprofloxacin was consistent with the kmcc and
the lung tissue binding may have decreased the knal value for tobramycin. In contrast,
calcitonin is a peptide and thus highly susceptible to proteolytic degradation by proteases
in the lung, including trypsin, chymotrypsin and aminopeptidase. This may have
contributed to its high knal values.
The ka values were shown to be well correlated with the drug’s MW, while also
being affected by regional deposition within the lung. The knal values were determined by
the presence of binding, local metabolism and mucociliary clearance. While similar
attempts should continue with different drugs, these results have suggested that this
curve fitting approach seems to be useful in deriving the accurate descriptors that
determine the lung disposition kinetics and predicting the lung kinetic behavior of new
drug entities in humans.
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CHAPTER 4
LUNG DISPOSITION KINETIC ANALYSIS VIA MOMENT-BASED APPROACH

4.1

Introduction
In Chapter 3, the inhaled PK profile data for three inhaled drugs (tobramycin,

calcitonin and ciprofloxacin) were analyzed with the lung deposition and disposition
compartment model by curve fitting approach. As a result, the kinetic descriptors of lung
absorption (ka) and non-absorptive loss (knal) were reasonably determined. In this chapter,
the same PK data sets were used with a different approach of the moment-based
analyses. The same lung disposition kinetic model was then applied to derive the k a and
knal values. The ka and knal values derived by these two different methods were finally
compared and discussed.

4.2

Methods

4.2.1 Literature data collection
The IV PK profile data and the inhaled -scintigraphy and PK profile data for
tobramycin, calcitonin and ciprofloxacin were those taken from the literature and used in
the curve fitting-based analysis of the lung disposition kinetics described in Chapter 3.
Table 4.1 lists the respective literature sources for each drug. The mean plasma/serum
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drug concentration vs. time profile data were extracted using GetData Graph Digitizer, as
completed in Chapter 3.

Table 4.1 Literature used in the moment-based lung disposition kinetics analyses.
Drug
IV PK
Inhaled -scintigraphy and PK
Tobramycin
Calcitonin
Ciprofloxacin

Pleasants et al., 1988
Buclin et al., 2002
Brunner et al., 1999

Newhouse et al., 2003
Clark et al., 2008
Stass et al., 2016

4.2.2 Moment-based analyses for IV and inhaled PK profiles
Moment-based PK profile analyses were carried out, as described in Gibaldi &
Perrier (1982). The total area under the plasma/serum concentration vs. time profile curve
(AUCtot) was first calculated by:
AUCtot = AUC0-last + AUClast-∞

Equation 4.1

where AUC0-last is the AUC between time 0 and the last sampling time (tlast), calculated by
the trapezoidal method; and AUClast-∞ is the extrapolated AUC after the last sampling time
up to time infinity, which was calculated by:
AUClast-∞ = CClast / 

Equation 4.2

where CClast is the plasma/serum concentration at the last sampling time; and  is the
terminal-phase slope in the semi-natural logarithmic plasma/serum concentration vs. time
plot. Separately, the total area under the moment plasma/serum concentration vs. time
profile curve (AUMCtot) was calculated by:
AUMCtot = AUMC0-last + AUMClast-∞

Equation 4.3
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where AUMC0-last is the AUMC between time 0 and the last sampling time (tlast), calculated
with the profile of [CC x time] vs. time by the trapezoidal method; and AUMClast-∞ is the
extrapolated AUMC after the last sampling time up to time infinity, which was calculated
by:
AUMClast-∞ = (CClast / 2) + (CClast ∙ tlast / )

Equation 4.4

Accordingly, the mean residence time (MRT) after administration was calculated by:
MRT = AUMCtot / AUCtot - Tdose / 2

Equation 4.5

where Tdose is the time required for constant rate administration, i.e., time of infusion or
nebulization and otherwise 0 for IV bolus and inhaled administration with DPI (or pMDI).
From the IV and inhaled PK profile data, the MRT values were respectively determined
by the method described above, as MRTiv and MRTinh.

4.2.3 Moment-based determination of lung disposition kinetic parameters
To analyze the lung disposition kinetics with these MRT values, the lung
disposition kinetic model used in the curve fitting approach in Chapter 3 and now shown
in Figure 4.1 was used in following the moment-based analysis described above. Given
the linear PK assumption, the MRT in the lung (MLRT) was calculated by:
MLRT = MRTinh - MRTiv

Equation 4.6

Now, in the model shown in Scheme 4.1, the lung absorption and non-absorptive loss
were kinetically rate-controlled with the respective rate constants, ka and knal, as assumed
in Chapter 3. Hence, by definition, the MLRT was described by:
MLRT = 1 / (ka + knal)

Equation 4.7

Notably, the fractional bioavailability of inhaled administration (FL) was also defined by:
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FL = ka / (ka + knal)

Equation 4.8

Therefore, from Equations 4.7 and 4.8, the ka and knal values were estimated with:
ka = FL / MLRT

Equation 4.9

knal = 1 / MLRT – ka

Equation 4.10

It should be noted that the FL value was calculated with the AUC values normalized with
dose for IV and inhaled administration, as described below:
FL = (AUCtot,inh/DTL) / (AUVtot,iv/Doseiv)

Equation 4.11

where Doseiv is the IV dose by bolus injection or infusion; and DTL is the dose to the lung
determined from -scintigraphy.

DTL

Lung

knal

ka

Systemic disposition

elimination

Figure 4.1 The lung deposition and disposition model that incorporates absorption and
non-absorptive loss, along with the systemic elimination. The lung receives dose-tothe lung (DTL) upon inhaled administration. Lung’s absorption and non-absorptive loss
are kinetically described with the first-order rate constants, ka and knal, respectively.
The systemic disposition kinetics were controlled not only with elimination from the
systemic circulation but also by lung absorption as the first-order input rate, ka.
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4.3

Results and Discussion

4.3.1 Tobramycin
The moment-based analyses of the IV and inhaled PK profile data for tobramycin
are summarized in Table 4.2. The derived lung disposition kinetic parameters, ka and knal,
are shown in Table 4.3 and compared with those derived by the curve fitting approach in
Chapter 3, as shown in Table 4.4. The ka and knal values for tobramycin inhaled with the
DPI and NEB were each bracketed by the 95% CI of the corresponding rate constant
values derived by the curve fitting approach.

Table 4.2 The IV and inhaled PK parameters for tobramycin in the moment-based
analyses.
PK parameter

IV

AUC0-last (mg/L*h)
Terminal slope  (h-1)
AUClast-∞ (mg/L*h)
AUCtot (mg/L*h)
AUMC0-last (mg/L*h2)
AUMClast-∞ (mg/L*h2)
AUMCtot (mg/L*h2)
MRT (h)

Inhalation
DPI
3.37
0.27
0.85
4.22
11.9
10.0
21.9
5.06

17.8
0.32
1.40
19.2
41.6
15.6
57.2
2.73

NEB
1.65
0.30
0.40
2.05
6.02
4.56
10.6
5.04

Table 4.3 The lung disposition kinetic parameters for tobramycin derived through the
moment-based analyses.
Lung disposition
parameter
MLRT (h)
1/MLRT (h-1)
FL
ka (h-1)
knal (h-1)

kinetic

DPI

NEB

2.34
0.43
0.94
0.40
0.03

2.32
0.43
0.84
0.36
0.07
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Table 4.4 The ka and knal values of tobramycin derived by the curve fitting- and momentbased approaches.
ka (h-1)
(95% CI)
Device
DPI
NEB

Curve
fitting
0.45
(0.35, 0.55)
0.34
(0.28, 0.40)

knal (h-1)
(95% CI)
Moment
analysis
0.40
0.36

Curve
fitting
0.08
(0.02, 0.17)
0.08
(0.01, 0.15)

Moment
analysis
0.03
0.07

4.3.2 Calcitonin
The moment-based analyses of the IV and inhaled PK profile data for calcitonin
are summarized in Table 4.5. The derived lung disposition kinetic parameters k a and knal
are shown in Table 4.6 and compared with those derived by the curve fitting approach in
Chapter 3, as shown in Table 4.7. The knal values for calcitonin inhaled with the DPI and
NEB were each bracketed by the 95% CI of the knal values derived by the curve-fitting
approach. However, the ka values derived were outside the 95% CI of the ka values
derived by the curve fitting approach. Notably, these values were greater than the upper
side of the 95% CI.
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Table 4.5 The IV and inhaled PK parameters for calcitonin in the moment-based
analyses.
PK parameter

IV

AUC0-last (µg/L*h)
Terminal slope  (h-1)
AUClast-∞ (µg/L*h)
AUCtot (µg/L*h)
AUMC0-last (µg/L*h2)
AUMClast-∞ (µg/L*h2)
AUMCtot (µg/L*h2)
MRT (h)

Inhalation
DPI
0.05
0.85
0
0.05
0.05
0
0.05
0.96

0.16
3.72
0
0.16
0.12
0
0.12
0.28

NEB
0.07
0.77
0
0.07
0.09
0
0.09
1.21

Table 4.6 The lung disposition kinetic parameters for calcitonin derived through the
moment-based analyses.
Lung disposition
parameter
MLRT (h)
1/MLRT (h-1)
FL
ka (h-1)
knal (h-1)

kinetic

DPI

NEB

0.68
1.47
0.07
0.10
1.37

0.93
1.08
0.08
0.09
0.99

Table 4.7 The ka and knal values of calcitonin derived by the curve fitting and momentbased approaches.
Device

DPI
NEB

ka (h-1)
(95% CI)
Curve
fitting
0.06
(0.04, 0.07)
0.05
(0.04, 0.06)

knal (h-1)
(95% CI)
Moment
analysis
0.10
0.09
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Curve
fitting
2.32
(1.24, 3.40)
1.22
(0.84, 1.61)

Moment
analysis
1.37
0.99

4.3.3 Ciprofloxacin
The moment-based analyses of the IV and inhaled PK profile data for ciprofloxacin
are summarized in Table 4.8. The contribution of AUClast-∞ to AUCtot was 26%, greater
than the gold standard of 20%. This may be because of insufficient sampling duration and
not the sampling intervals, because Brunner et al. employed sufficient number of
sampling intervals over the 8 h sampling duration. The derived lung disposition kinetic
parameters ka and knal are shown in Table 4.9 and compared with those derived by the
curve fitting approach in Chapter 3, as shown in Table 4.10. The ka value for ciprofloxacin
inhaled with the DPI was bracketed by the 95% CI of the corresponding rate constant
value derived by the curve fitting approach. However, the knal value derived was outside
the 95% CI of the knal value derived by the curve fitting approach. Notably, this value was
smaller than the lower side of the 95% CI.

Table 4.8 The IV and inhaled PK parameters for ciprofloxacin in the moment-based
analyses.
PK parameter
AUC0-last (mg/L*h)
Terminal slope  (h-1)
AUClast-∞ (mg/L*h)
AUCtot (mg/L*h)
AUMC0-last (mg/L*h2)
AUMClast-∞ (mg/L*h2)
AUMCtot (mg/L*h2)
MRT (h)

IV

Inhalation
DPI
0.18
0.17
0.03
0.21
0.75
0.59
1.35
6.39

2.39
0.18
0.85
3.25
6.92
11.6
18.5
5.61
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Table 4.9 The lung disposition kinetic parameters for ciprofloxacin derived by the
moment-based analyses.
Lung disposition kinetic parameter
MLRT (h)
1/MLRT (h-1)
FL
ka (h-1)
knal (h-1)

DPI
0.78
1.28
0.78
1.00
0.28

Table 4.10 The ka and knal values of ciprofloxacin derived by the curve fitting- and
moment-based approaches.
ka (h-1)
(95% CI)
Device
DPI

Curve
fitting
0.98
(0.71, 1.25)

knal (h-1)
(95% CI)
Moment
analysis
1.00

Curve
fitting
0.61
(0.36, 0.86)

Moment
analysis
0.28

4.4 Comparison between moment-based analysis and curve fitting-based
approaches
Moment analysis-based approach was successfully used to derive the ka and knal
values for all three drugs. This approach employed the same IV and inhaled PK profile
data as those used in the curve fitting-based approach in Chapter 3. The approach used
integrated equations to calculate the AUC and AUMC of the plasma/serum concentrationtime curves, followed by the use of the lung disposition PK model to derive the k a and knal
values. In contrast, the curve fitting approach used differential equation-based non-linear
regression, in which IV PK parameters were fixed to derive the ka and knal values. Note
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that, in the curve fitting, the ka and knal values were derived by fitting the PK profile data
up to the last sampling time point (tlast).
The ka and knal values for tobramycin (both DPI and NEB) and ka value for
ciprofloxacin (DPI) were each derived within the 95% CI of the corresponding rate
constant values for the curve fitting approach. The knal values for calcitonin (DPI/NEB)
were also within the 95% CI of the values for the curve fitting approach. However, the ka
values for calcitonin (both DPI and NEB) and knal value for ciprofloxacin were outside the
95% CI of the respective values derived by the curve fitting approach. In fact, calcitonin
ka values were greater than the upper side of the 95% CI and ciprofloxacin knal value was
lower than the lower side of the 95% CI. It is speculated that this over-estimation of the
ka values and under-estimation of the knal values by the moment analysis-based approach
may be due to its use of the AUC and AUMC beyond the tlast.
Despite the slight inconsistencies in the values derived by the curve fitting- and
moment analysis-based approaches as described above, it was observed that the ka
values derived by moment analysis still found a good correlation with the 1/(MW)1/3 of the
drug molecules when plotted alongside the curve fitting-based ka values, as depicted in
Figure 4.1, yielding equation log [ka] = 2.3 + 3.0 x log [1/(MW)1/3] (R2= 0.92).
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Figure 4.2 Correlation between curve fitting- and moment analysis-based ka and
1/(MW)1/3 for tobramycin, calcitonin and ciprofloxacin.

4.5

Conclusions
Using the inhaled and IV PK profiles alongside the DTL from the scintigraphic

lung deposition data in the literature, the lung disposition kinetic descriptors (ka and knal)
were successfully derived for the three drugs delivered by DPI and/or NEB via the
moment analysis-based approach. The values derived by these two approaches are
summarized in Table 4.11. In addition, the ka and knal values were comparable to those
derived by the curve fitting-based approach in the majority of the cases. Thus, it is now
possible to derive the lung disposition kinetics by this moment analysis-based approach,
even though the data set are not compatible to the curve fitting approaches such as when
AUC and MRT are the only available information pertinent to a drug molecule. However,
the curve fitting approach can give statistical information like 95% CI, COD and MSC, and
therefore, would provide greater confidence in their derived values.

60

Table 4.11 Physiochemical properties and the ka and knal values derived by the curve fitting and moment analysis
approaches for tobramycin, calcitonin and ciprofloxacin.
Drug
Tobramycin

Calcitonin

MW
(Da)

Log
KD

Inhaler
device

P/C
ratio

468

-10

DPI

1.6±0.4

NEB

1.5±0.4

DPI

0.8±0.3

NEB

1.4±0.3

DPI

0.6

3,432

Ciprofloxacin 331

-33

-2

-1

ka (h ) (95% CI)
Curve fitting
0.45
(0.35, 0.55)
0.34
(0.28, 0.40)
0.06
(0.04, 0.07)
0.05
(0.04, 0.06)
0.98
(0.71, 1.25)

P/C ratio: Peripheral-to-central deposition ratio
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Moment analysis
0.40
0.36
0.10
0.09
1.00

-1

knal (h ) (95% CI)
Curve fitting
0.08
(0.02, 0.17)
0.08
(0.01, 0.15)
2.32
(1.24, 3.40)
1.22
(0.84, 1.61)
0.61
(0.36, 0.86)

Moment analysis
0.03
0.07
1.37
0.99
0.28

Chapter 5
EFFECTS OF LUNG DELIVERY AND DISPOSITION KINETIC CHANGES ON
SYSTEMIC PK AND LUNG EXPOSURE PROFILES VIA SIMULATION

5.1

Introduction
In Chapters 3 and 4, the inhaled PK profile data for the three drugs, tobramycin,

calcitonin and ciprofloxacin, have successfully derived the kinetic descriptors for lung
disposition by the curve fitting and moment-based approaches, respectively. In both
approaches, the identical kinetic compartment model was assumed for lung disposition,
thereby resulting in plausible and comparable kinetic rate constants for lung absorption
(ka) and non-absorptive loss (knal). However, only the mean PK profile data were used, so
that how variance of the PK profile data affects derivation of these kinetic descriptors is
uncertain. Conversely, from the bioequivalence regulation perspective, how variance or
difference of each of the kinetic descriptors affects the systemic PK and local lung
exposure profile outcomes would be of interest in order to identify the key attribute(s)
within the lung. Hence, this chapter used the kinetic rate constants derived through the
curve fitting in Chapter 3 as the reference standard conditions and simulated the PK and
lung exposure profiles upon a 20 % positive or 20 % negative change in each of the DTL,
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ka and knal values. By so doing, likely changes in the model’s predictions for the
plasma/serum PK metrics, Cmax, AUC and Tmax, and for the local lung exposure metrics,
AUClung (area under the drug mass in the lung vs. time curve) and LRT0.5 (lung residence
half-life), were identified and discussed for each of the three drugs.

5.2

Methods

5.2.1 Models and reference standard conditions
Figure 5.1 describes the kinetic models and their model parameters and the DTL
used as the reference standard conditions for A) tobramycin, B) calcitonin and C)
ciprofloxacin. These were derived in Chapter 3 as the parameter estimates to best explain
each of the inhaled PK profiles of the literature. Note that the model parameters for
tobramycin and calcitonin were those for DPI, like ciprofloxacin.

A. Tobramycin

27.4 mg

0.08 h-1

Lung

0.45 h-1
11.4 L
Central
compartment

0.53 h

0.36 h

0.69 h
-1
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-1

-1

Peripheral
compartment

52.9 µg

B. Calcitonin

2.32 h-1

Lung

0.06 h-1
17.9 L
Central
compartment

3.72 h
C. Ciprofloxacin

-1

16.58 mg

0.61 h-1

Lung

0.98 h-1
93.2 L
Central
compartment

0.64 h

1.42 h

0.86 h

-1

-1

Peripheral
compartment

-1

Figure 5.1 The kinetic models and their parameters and the DTL used as the reference
standard conditions for A) tobramycin, B) calcitonin and C) ciprofloxacin. These
parameters were derived in Chapter 3 as the parameter estimates to best explain each
of the inhaled PK profiles of the literature.
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5.2.2 Systemic PK profile simulation upon ±20 % changes of the DTL, ka and knal
With the models shown above, the DTL, ka and knal values were each changed to
a 20 % positive or a 20 % negative value, and the plasma/serum PK profiles were then
predicted by simulation using Scientist. All the remaining parameters were fixed, as
shown in Fig. 5.1. Simulation prediction was made every 1 min over the period of 8 h for
tobramycin and ciprofloxacin and 6 h for calcitonin, as used in the literature. The Cmax and
Tmax were identified from the predicted profile data, while the AUC was calculated by the
trapezoidal method plus the residual area calculation, as described in Chapter 4.

5.2.3 Local lung exposure profile simulation upon ±20 % changes of the DTL, k a
and knal
From the kinetic models shown in Figure 5.1, the drug mass remaining in the lung
(ML) at a given time was described by:
dML/dt = -(ka+knal)*ML

Equation 5.1

where ML was DTL at time 0, i.e., immediately after inhaled administration. Hence, the
local lung exposure profiles were predicted by simulation with the k a and knal values and
the DTL with or without positive and negative 20 % changes using Scientist. Like the
systemic PK profile simulation, simulation prediction was made every 1 min over the
period of 8 h for tobramycin and ciprofloxacin and 6 h for calcitonin, as used in the
literature. With the predicted profile data, the AUClung (area under the drug mass in the
lung vs. time curve) was calculated by the trapezoidal method plus the residual area
calculation; and the LRT0.5 (lung residence half-life) was by:
LRT0.5 = 0.693 / (ka+knal)

Equation 5.2
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Graphically, the slope of the semi-natural logarithmic local lung exposure profile
corresponded to the (ka+knal) value.

5.3

Results and Discussion

5.3.1 Systemic PK profile simulation upon ±20 % changes of the DTL, ka and knal
5.3.1.1 Tobramycin
The simulation results of ±20 % changes of the DTL, ka and knal to the serum
concentration vs. time profile and its PK metrics for tobramycin are shown in Figure 5.2A. When the DTL was changed by ±20 %, the Cmax and AUC∞ were identically changed
by ±20 %, respectively, while the Tmax was unchanged. These identical changes in the
Cmax and AUC∞ were simply a reflection of linear lung disposition and systemic kinetics
and PK. The ±20 % changes in the ka resulted in 11 or 13 % changes in the Cmax, 3 or 5
% changes in the AUC∞ and 9 or 11 % changes in the Tmax. This indicated that the Cmax
and Tmax were more influenced by changes in the ka than the AUC∞. This may be
attributed to the fact that the Cmax (a measure of the rate and extent of absorption) and
Tmax (a measure of rate of absorption) were primarily determined by the sum of the ka and
knal, but for tobramycin, the ka was a predominant contributor (by 85 %). It should be noted
that the positive and negative 20 % changes did not give identical % changes in any of
the parameters. The 20 % changes in knal (i.e., the minor contributor) resulted in only
small 2-4 % changes in the Cmax, AUC∞ and Tmax.

66

5.3.1.2 Calcitonin
The simulation results of ±20 % changes of the DTL, ka and knal to the plasma
concentration vs. time profile and its kinetic parameters for calcitonin are shown in Figure
5.2-B. As seen for tobramycin, the ±20 % changes in DTL caused identical ±20 %
changes in the Cmax and AUC∞, but no change in the Tmax. Similarly, the ±20 % changes
in the ka resulted in ±20 % changes in the Cmax and AUC∞, but again no changes in the
Tmax. This may be because, for calcitonin, the ka is a significantly minor contributor of
ka+knal, so that the ±20 % changes in the ka did not cause significant changes to the rate
of absorption. While the Cmax and AUC∞ were suggested to be more influenced by the
changes in the ka than the Tmax, these changes were different from the changes seen for
tobramycin, presumably because of the fact that the ka was much smaller than the knal for
calcitonin and thus, the ka changes did not cause changes in the sum of the k a and knal.
In contrast, the ±20 % changes in the knal resulted in 8 or 9 % changes in the Cmax, 16 or
24 % changes in the AUC∞, and 10 % changes in the Tmax. These changes in the kinetic
parameters were likely because the sum of the ka and knal changed by a greater extent
with the changes in the knal.

5.3.1.3 Ciprofloxacin
The simulation results of ±20 % changes of the DTL, ka and knal to the plasma
concentration vs. time profile and its kinetic parameters for ciprofloxacin are shown in
Figure 5.2-C. When the DTL was changed by ±20 %, the Cmax and AUC∞ were identically
changed by ±20 %, respectively, while the Tmax was unchanged. These identical changes
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in the Cmax and AUC∞ were simply a reflection of linear lung disposition kinetics and PK.
The ±20 % changes in the ka resulted in 13 or 15 % changes in the Cmax, 7 or 9 % changes
in the AUC∞ and 8 or 10 % changes in the Tmax. This indicated that the Cmax and Tmax
were marginally more influenced by changes in the ka than the AUC∞. This may again be
attributed to the fact that the Cmax (a measure of the rate and extent of absorption) and
Tmax (a measure of rate of absorption) were primarily determined by the sum of the ka and
knal, but for ciprofloxacin, the ka was a predominant contributor (by 62 %). Note that the
positive and negative 20 % changes did not give identical % changes in any of the
parameters. The 20 % changes in the knal (the minor contributor) resulted in smaller ~4
% changes in the Cmax and 5 % changes in the Tmax.

5.3.1.4. Systemic PK profile simulation for three molecules
Across three molecules, when the ka was increased, the AUC∞ (i.e., the extent of
absorption) was increased. In general, increasing either the ka or knal causes the sum of
the ka and knal, i.e., (ka+knal), to be increased, and because the (ka+knal) determines the
rate of absorption, increasing either the ka or knal shortened the Tmax. Because the Cmax is
determined by both the rate and extent of absorption, changes in either the k a or knal
changed the Cmax. For calcitonin, the ka was ~3 % of the (ka+knal) and hence, changes in
the ka didn’t much change the (ka+knal). This may also be the reason for no changes in
the Tmax in response to the ka changes. For the simplest case scenario of a bolus DPI
inhalation and one-compartment model shown for calcitonin in Figure 5.1-B, the Tmax and
Cmax are described by the following equation as derived from Gibaldi & Perrier (1982):
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Tmax=

2.303
* log (ka+knal)
(ka+knal) – k10
k10

Equation 5.1

Cmax= FL * DTL e- k10*Tmax

Equation 5.2

VC
where k10 is the first-order elimination rate constant from the central compartment and FL
is fractional pulmonary bioavailability. Thus, for calcitonin, the ka or knal increase led to an
increase in the (ka+knal) and subsequently to a shorter Tmax. Similar analogy may be
applied to a bolus DPI inhalation and two-compartment model, wherein, an increase in
(ka+knal) led to a shorter Tmax.
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A. DTL

B. ka

C. knal

Figure 5.2-A Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the serum tobramycin concentration vs.
time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values. The
profiles in blue are drawn by simulation using DTL= 27.4 mg, k a= 0.45 h-1 and knal= 0.08 h-1, as derived by the curvefitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon +20
and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived through
the curve-fitting.
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A. DTL

B. ka

C. knal

Figure 5.2-B Effects of ±20% changes in the A) DTL, B) ka and C) knal values on the plasma calcitonin concentration vs.
time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values. The
profiles in blue are drawn by simulation using DTL= 52.9 µg, ka= 0.06 h-1 and knal= 2.32 h-1, as derived by the curvefitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon +20
and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived
through the curve-fitting.
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A. DTL

B. ka

C. knal

Figure 5.2-C Effects of ±20% changes in the A) DTL, B) ka and C) knal values on the plasma ciprofloxacin concentration
vs. time profiles following inhaled administration in healthy subjects and % changes in the Cmax, AUC∞ and Tmax values.
The profiles in blue are drawn by simulation using DTL= 16.58 mg, k a= 0.98 h-1 and knal= 0.61 h-1, as derived by the
curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation upon
+20 and -20 % change in the parameter of interest, while the remainders were held consistent with the values derived
through the curve-fitting.
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5.3.2 Local lung exposure profile simulation upon ±20 % changes of the DTL, ka
and knal
5.3.2.1 Tobramycin
Figure 5.3-A shows the simulation results of ±20 % changes of the DTL, ka and knal
to the tobramycin mass remaining in the lung vs. time profiles and lung exposure kinetic
parameters, AUClung and LRT0.5. When the DTL was changed by ±20 %, the AUClung was
identically changed by ±20 %, while the LRT0.5 was unchanged, as similarly seen in the
PK profile in Figure 5.2-A. In contrast, with the ±20 % changes in the ka, both the AUClung
and LRT0.5 changed by 14 or 19 % and 15 or 21 %, respectively. However, with the ±20
% changes in the knal, the changes in the AUClung and LRT0.5 were small and ~4 %. These
may be again consistent with the fact that, for tobramycin, the k a was kinetically a
predominant contributor (by 85 %) in the lung exposure profile, given its rate-control by
the sum of the ka and knal.

5.3.2.2 Calcitonin
Figures 5.3-B shows the simulation results of ±20 % changes of the DTL, k a and
knal to the calcitonin mass remaining in the lung vs. time profiles and lung exposure kinetic
parameters, AUClung and LRT0.5. As was the case for tobramycin, the ±20 % changes in
the DTL identically changed the AUClung by ±20 %, while the LRT0.5 was unchanged. With
the ±20 % changes in the ka, both the AUClung and LRT0.5 changed by only 0.5 %.
However, with the ±20 % changes in the knal, the changes in both AUClung and LRT0.5
were much greater, 16 or 24 %. These were consistent with the fact that, for calcitonin,
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the knal was kinetically a predominant contributor (by 97.5 %) in the lung exposure profile,
given its rate control by the sum of the ka and knal.

5.3.2.3 Ciprofloxacin
Figure 5.3-C shows the simulation results of ±20 % changes of the DTL, k a and
knal to the ciprofloxacin mass remaining in the lung vs. time profiles and lung exposure
kinetic parameters, AUClung and LRT0.5. When the DTL was changed by ±20 %, the
AUClung was identically changed by ±20 %, while the LRT0.5 was unchanged. In contrast,
with the ±20 % changes in the ka, both the AUClung and LRT0.5 changed by 11 or 14 %.
However, with the ±20 % changes in the knal, the changes in both AUClung and LRT0.5
were smaller, 7 or 8 %. These may be again consistent with the fact that, for ciprofloxacin,
the ka was kinetically a major contributor (by 62 %) in the lung exposure profile, given its
rate-control by the sum of the ka and knal.

5.3.2.4 Local lung exposure profile simulation for three molecules
For all three molecules, ±20 % changes in the DTL produced identical ±20 %
changes in the AUClung, while the LRT0.5 remained unchanged as this parameter is doseindependent. For any changes in the ka and knal, the AUClung and LRT0.5 changed and the
changes were dependent on the relative contribution of the k a and knal, as related to the
changes in the (ka+knal). In other words, changes made to the major contributor of ka+knal
caused greater changes in the AUClung and LRT0.5, compared to changes made to the
minor contributor.
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A. DTL

B. ka

C. knal

Figure 5.3-A Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the tobramycin drug mass remaining in
the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUClung and LRT0.5
values. The profiles in blue are drawn by simulation using DTL= 27.4 mg, k a= 0.45 h-1 and knal= 0.08 h-1, as derived by
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation
upon +20 and -20 % change in the parameter of interest.
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A. DTL

B. ka

C. knal

Figure 5.3-B Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the calcitonin drug mass remaining in
the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUC lung and LRT0.5
values. The profiles in blue are drawn by simulation using DTL= 52.9 µg, k a= 0.06 h-1 and knal= 2.32 h-1, as derived by
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation
upon +20 and -20 % change in the parameter of interest.
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A. DTL

B. ka

C. knal

Figure 5.3-C Effects of ±20 % changes in the A) DTL, B) ka and C) knal values on the ciprofloxacin drug mass remaining
in the lungs vs. time profiles following inhaled administration in healthy subjects and % changes in the AUC lung and LRT0.5
values. The profiles in blue are drawn by simulation using DTL= 16.58 mg, k a= 0.98 h-1 and knal= 0.61 h-1, as derived by
the curve-fitting of the profile data in the literature in Chapter 3. The profiles in orange and gray are drawn by simulation
upon +20 and -20 % change in the parameter of interest.
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5.4

Conclusions
In this chapter, simulation was used to study the effects of ±20 % changes in drug

delivery (DTL) and lung disposition kinetics (ka and knal) on the systemic PK and local lung
exposure profiles following inhaled administration. It was clear that the DTL changes
caused identical changes in the Cmax and AUC∞ and did not affect the Tmax across all three
drugs. In contrast, the impact of the ka and knal changes on the changes in Cmax, AUC∞
and Tmax appeared to depend on how each kinetic process (ka or knal) contributes to the
overall rate of drug disposition in the lung. Similarly, the local lung exposure was a direct
correlation with the sum of the ka and knal and thus, its impact again depended on how
each kinetic process (ka and knal) contributes to the overall rate of drug disposition in the
lung.
The FDA bioequivalence criteria states that a test product is bioequivalent to a
reference product, when the 95 % confidence interval (CI) of the test product exposure
metrics (i.e., Cmax and AUC∞) falls within 80-125 % range of those for the reference
product. This was with the understanding that the 80-125 % range of the Cmax and AUC∞
represents a ±20 % of the systemic exposure. Therefore, as a starting point, it was of
interest to perform simulations to understand what % changes were observed in the Cmax
and AUC∞ by introducing ±20 % changes in the DTL, ka and knal. While further simulations
with different molecules are necessary to identify a more solid trend or classification
regarding changes in the kinetic metrics, these simulation strategies can be an important
tool to allow us studying changes in the PK metrics in response to drug delivery (DTL)
and lung disposition kinetics (ka and knal).
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CHAPTER 6
OVERALL CONCLUSIONS, LIMITATIONS AND FUTURE DIRECTIONS

This thesis project aimed to develop the lung deposition and disposition kinetic
model to derive and predict the kinetic descriptors of lung disposition, namely, the rate
constants for absorption (ka) and non-absorptive loss (knal). The model incorporated the
dose delivered to the lung (DTL) and the first-order ka and knal in the lung, along with oneor two-compartment kinetic model for first-order systemic disposition. Appropriate
selection of drugs and study design allowed elimination of gastrointestinal (GI) absorption
from this model. An exhaustive literature search found that three drugs, tobramycin,
calcitonin and ciprofloxacin, published all necessary data sets, i.e., intravenous (IV) PK
profiles, inhaled PK profiles without GI absorption and corresponding lung deposition data
by -scintigraphy.
The two approaches of curve fitting- and moment analysis-based approaches were
developed and used to derive the ka and knal values for the three drugs delivered via dry
powder inhalers (DPIs) and/or nebulizers (NEB). In the curve fitting approach, each
inhaled PK profile data were fitted to the model to derive the k a and knal values, while the
DTL was fixed, as reported by the-scintigraphy data, and the systemic PK parameters
were derived and fixed with the IV PK profiles. All the curve fittings showed acceptable
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“goodness-of-fit” to the profiles in the literature. The ka values for all the three hydrophilic
drug molecules were well correlated to their molecular weight. The k nal values appear to
be well aligned with the literature reporting tissue binding, lung metabolism and
mucociliary clearance. In the moment-based analysis, the same data sets were used. The
MRTiv and MRTinh were calculated after IV and inhaled administration, respectively, to
estimate the mean lung residence time (MLRT) after inhalation. With the DTL, the
bioavailability due to lung absorption (FL) was also determined. Given FL = MLRTka =
ka/(ka+knal), the ka and knal values were then derived, which were found to be comparable
to those derived by the curve fitting in majority of the cases.
The curve fitting derived ka and knal values were used to predict the systemic PK
and local lung exposure profiles by simulation upon ±20 % changes in lung delivery (DTL)
and lung disposition (ka and knal). The DTL changes caused identical changes in the Cmax
and AUC∞ without changing the Tmax across all three drugs. In contrast, impacts of the ka
and knal changes to the Cmax, AUC∞ and Tmax appeared to depend on how each process
(ka or knal) contributes to the overall rate of drug disposition in the lung.

One of the significant limitations of this thesis research is a use of mean PK profile
data from the literature by extraction, so that original PK data variability could not be taken
into account in the ka and knal derivation. In addition, the lung disposition model was
minimalist, combining multiple non-absorptive clearances into one first-order kinetic
process and disregarding possible within-lung kinetic differences. While incorporating
detailed distinctions would be ideal to understand the lung region-dependent disposition
kinetics, it would not derive such many parameter estimates in an accurate manner, as
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has been obtained in this thesis research. The data availability is also a limitation. The
inhaled PK profile data and corresponding -scintigraphic lung deposition data are
required along with the IV PK profile data. For the moment analysis-based approach, this
limitation may be eased, if the DTL, AUC and MRT values are reported in the literature
despite a lack of the PK profile data points. Even so, this approach does not provide
statistics for “goodness”, so that assessment and comparison of the derived k a and knal
values would still remain difficult.

This project has attempted to resolve the kinetic complexities by lung delivery,
deposition and disposition to understand and identify critical factors and attributes that
contribute to outcome measures of systemic PK and local lung exposure profiles. While
the project has been successful with the three drug molecules of its choice, it is clear that
the study should be extended to more molecules with different physicochemical
properties and indications to further solidify the utility of the approaches. Particularly,
fluticasone propionate would be of most interest, as to recent efforts of developing its
generic inhaler products.
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APPENDIX A

METHOD OF RESIDUALS USED FOR DERIVING INITIAL PARAMETER
ESTIMATES OF IV PK PROFILE

This Appendix will briefly describe the steps involved in estimating the initial
estimates of model parameters after IV administration as detailed in Gibaldi & Perrier
(1982).
When the drug follows a one-compartment model after zero-order input and its
elimination rate constant is first-order like in case of calcitonin, the concentration of the
drug in central compartment as a function of time can be derived by:
CC= k0 * (1- e-k10*t)

Equation A.1

VC * k10
where CC is the concentration of drug in the central compartment (plasma/serum drug
concentration) at time t, k0 is the zero-order infusion rate for IV infusion during the infusion
period; k10 is the first-order elimination rate constant from the central compartment; VC is
the apparent volume of distribution of the central compartment. Equation A.1 was used
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to calculate initial estimates of one-compartment model parameters k10 and VC for
calcitonin to explain the IV PK profile after IV infusion reported in Buclin et al.
When the drug follows a two-compartment model like in case of tobramycin and
ciprofloxacin, the concentration in the central compartment as a function of time can be
derived by the following biexponential equation after administration of drug intravenously
as a bolus or at a constant rate infusion:
CC= A*e-αt + B*e-βt

Equation A.2

where CC is the concentration of drug in the central compartment (plasma/serum drug
concentration) at time t; α, β are apparent first order fast (distribution and elimination) and
slow (elimination) disposition rate constants, respectively; and A and B are zero-time
intercepts corresponding to α and β, respectively.
The pharmacokinetic macro-rate constants A, α, B and β in equation A.2 can be
derived from the biexponential central compartment drug concentration (CC) versus time
curve by using method of residuals. (Gibaldi & Perrier 1982) Method of residuals is a PK
technique for resolving a curve into its various exponential components. Since α is larger
than β, by definition, the term A*e-αt will approach zero more rapidly than B*e-βt and
equation A.2 will then reduce to equation A.3:
CC= B*e-βt

Equation A.3

Equation A.3 in natural-logarithmic terms will be:
Ln CC= Ln B – βt

Equation A.4
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This equation describes the terminal linear phase of the curve resulting from a plot of the
natural-logarithm of plasma/serum drug concentration versus time. This terminal linear
phase has a slope of -β, and when extrapolated to zero, it yields an intercept of Ln B.
By subtracting the concentration-time values on the extrapolated line from the
corresponding true plasma concentration-time values, a series of residual concentration
(Cr)-time values will be obtained, which are described as in equation A.5:
Cr= A*e-αt

Equation A.5

Equation A.5 in natural-logarithmic terms will be:
Ln Cr= Ln A – αt

Equation A.6

Thus, a plot of the natural-logarithm of the residual concentration values versus time will
yield a straight line with a slope of -α and a zero-time intercept of Ln A. Resolution of the
biexponential curve thereby enables the determination of all parameters in equation A.2,
which will in turn permit the estimation of the two-compartment model parameters k21, k10,
and k12 by using the following equations:

k21= Aβ+ Bα

Equation A.7

A+B
k10= α* β

Equation A.8

k21
k12= α + β – k21 – k10

Equation A.9

These steps to calculate two-compartment model parameters after IV
bolus/infusion were then followed to calculate initial estimates of model parameters k10,
90

k12, k21 and VC for tobramycin and ciprofloxacin to explain the IV PK profile after IV infusion
reported in Pleasants et al. and Brunner et al., respectively.
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APPENDIX B

ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR TOBRAMYCIN IV
AND INHALED PK PROFILES

Table B.1 Tobramycin mean serum concentration vs. time profile data reported in
Pleasants et al. after IV infusion.
T (h)
0.17
0.33
0.50
0.67
0.83
1.00
1.33
1.50
1.67
2
2.5
3
4
6
8

Mean serum concentration (mg/L)
3.8267
6.05078
8.18939
7.18595
6.37492
6.07669
4.90413
4.18039
3.67043
2.94884
2.56958
2.10497
1.56
0.811938
0.448589
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Table B.2 Macro-rate constants derived from tobramycin IV PK profile reported in
Pleasants et al. by using method of residuals.
A (mg/L)
α (h-1)
B (mg/L)
β (h-1)

8.76
1.65
5.53
0.32

The macro-rate constants in Table B.2 were used to calculate initial estimates of k10,
k12, k21 and VC which are reported in Chapter 3.
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A)
// Tobramycin IV Two Compartment Model File
IndVars: T
DepVars: CC
Params: VC, k10, k12, k21
//INPUT
Dose=118.2
TINF1=0.5
RATEON1=Dose/TINF1
TON1=0
TOFF1=TON1+TINF1
FLAGON1=UNIT(T-TON1)
FLAGOFF1=UNIT(T-TOFF1)
ARATE1=RATEON1*FLAGON1*(1-FLAGOFF1)
MC'=ARATE1+k21*MP-(k12+k10)*MC
MP'=k12*MC-k21*MP
B)
CC=MC/VC
Parameter Value
//Initial conditions
Name
T=0
VC
11.4
MC=0
k10
0.53
MP=0
***
k12
0.36
C)
k21
0.69
T (h)
0.17
0.33
0.50
0.67
0.83
1.00
1.33
1.50
1.67
2
2.5
3
4
6
8

Lower
Limit
0
0
0
0

Upper
Limit
Infinity
Infinity
Infinity
Infinity

Fixed?
Yes
Yes
Yes
Yes

Predicted serum concentration (mg/L)
3.2811
5.9637
8.4579
7.3666
6.5131
5.7559
4.6225
4.1703
3.7861
3.1897
2.5444
2.0917
1.4911
0.82231
0.46466

Figure B.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist ® for
curve-fitting the mean serum concentration vs. time profile of tobramycin following IV
infusion.
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Table B.3 Goodness-of-fit statistics and statistical output for tobramycin IV PK profile
curve fitting.
Goodness-of-fit statistics
Weighted
Unweighted
Sum of squared observations:
325.55
325.55
Sum of squared deviations:
0.68872
0.68872
Standard deviation of data:
0.25022
0.25022
R-squared:
0.99788
0.99788
Coefficient of determination:
0.9912
0.9912
Correlation:
0.99585
0.99585
Model Selection Criterion:
4.1997
4.1997
Confidence Intervals
Parameter Name:
VC
Estimated Value:
11.376
Standard Deviation:
0.42058
95% Range (Univariate):
10.45
12.302
95% Range (Support Plane):
9.8349
12.917
Parameter Name:
k10
Estimated Value:
0.53304
Standard Deviation:
0.054272
95% Range (Univariate):
0.41359
0.65249
95% Range (Support Plane):
0.33417
0.7319
Parameter Name:
k12
Estimated Value:
0.36143
Standard Deviation:
0.10101
95% Range (Univariate):
0.1391
0.58376
95% Range (Support Plane):
0.0087132
0.73157
Parameter Name:
k21
Estimated Value:
0.69437
Standard Deviation:
0.35579
95% Range (Univariate):
0.088723
1.4775
95% Range (Support Plane):
0.60935
1.9981
Variance-Covariance Matrix
0.17689
-0.012348
0.0029454
-0.033879
0.0013208
0.010204
-0.086985
0.015858
0.020584
Correlation Matrix
1
-0.54099
1
-0.79744
0.24093
1
-0.5813
0.82127
0.57272
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Table B.4-A Tobramycin mean (±SD) serum concentration vs. time profile data reported
in Newhouse et al. after inhalation from DPI.
T (h)
0
0.25
0.5
1
1.5
2
3
4
6
8

Mean serum concentration (mg/L)
0
0.36923
0.42528
0.56703
0.57363
0.56044
0.53571
0.45659
0.33626
0.23077

SD (mg/L)
0
0.134998
0.127047
0.182634
0.164767
0.15684
0.125062
0.113151
0.087345
0.06

Table B.4-B Tobramycin mean (±SD) serum concentration vs. time profile data reported
in Newhouse et al. after inhalation from NEB.
T (h)
0
0.25
0.5
1
1.5
2
3
4
6
8

Mean serum concentration (mg/L)
0
0.15041
0.17851
0.25893
0.26116
0.26446
0.26116
0.23141
0.17686
0.12066
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SD (mg/L)
0
0.091
0.08
0.103
0.091
0.089
0.077
0.07
0.052
0.052

A)
//Tobramycin lung deposition and disposition PK model
IndVars: T
DepVars: CC
Params: Dose, VC, k10, k12, k21, ka, knal
ML'=-(ka+knal)*ML

B)

MC'=k21*MP-(k12+k10)*MC+ka*ML

Parameter Parameter Lower
Name
Value
Limit
Dose
27.4
0
(DPI)
Dose
15
0
(NEB)
VC
11.4
0
k10
0.53
0
k12
0.36
0
k21
0.69
0
ka (DPI)
0.45
0
knal (DPI)
0.08
0

Upper
Limit
Infinity

Fixed?

Infinity

Yes

Infinity
Infinity
Infinity
Infinity
Infinity
Infinity

Yes
Yes
Yes
Yes
Yes
Yes

ka (NEB)
knal (NEB)

Infinity
Infinity

Yes
Yes

MP'=k12*MC-k21*MP
CC=MC/VC
//Initial conditions
T=0
ML=Dose
MC=0
MP=0

Yes

***
0.34
0.08

0
0

C)
T (h)
0
0.25
0.5
1
1.5
2
3
4
6
8

DPI
Predicted serum
concentration (mg/L)
0
0.22763
0.38466
0.55816
0.6196
0.62223
0.55315
0.4572
0.28769
0.17271

T (h)
0
0.25
0.5
1
1.5
2
3
4
6
8

NEB
Predicted serum
concentration (mg/L)
0
0.095597
0.16382
0.2446
0.27948
0.28876
0.27092
0.23507
0.16033
0.10243

Figure B.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist® for
curve-fitting the mean serum concentration vs. time profiles of tobramycin following
inhalation from DPI and NEB.
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Table B.5-A Goodness-of-fit statistics and statistical output for tobramycin DPI PK
profile curve fitting.
Goodness-of-fit statistics
Weighted
Unweighted
Sum of squared observations:
1.9437
1.9437
Sum of squared deviations:
0.033747
0.033747
Standard deviation of data:
0.064949
0.064949
R-squared:
0.98264
0.98264
Coefficient of determination:
0.88728
0.88728
Correlation:
0.96655
0.96655
Model Selection Criterion:
1.7829
1.7829
Confidence Intervals
Parameter Name:
ka
Estimated Value:
0.45025
Standard Deviation:
0.041451
95% Range (Univariate):
0.35467
0.54584
95% Range (Support Plane):
0.32647
0.57404
Parameter Name:
knal
Estimated Value:
0.076506
Standard Deviation:
0.042511
95% Range (Univariate):
0.021525
0.17454
95% Range (Support Plane):
0.050444
0.20346
Variance-Covariance Matrix
0.0017182
0.00086527
0.0018072
Correlation Matrix
1
0.49104
1
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Table B.5-B Goodness-of-fit statistics and statistical output for tobramycin NEB PK
profile curve fitting.
Goodness-of-fit statistics
Weighted
Unweighted
Sum of squared observations:
0.42727
0.42727
Sum of squared deviations:
0.0050663
0.0050663
Standard deviation of data:
0.025165
0.025165
R-squared:
0.98814
0.98814
Coefficient of determination:
0.92196
0.92196
Correlation:
0.97592
0.97592
Model Selection Criterion:
2.1505
2.1505
Confidence Intervals
Parameter Name:
ka
Estimated Value:
0.34124
Standard Deviation:
0.024899
95% Range (Univariate):
0.28382
0.39866
95% Range (Support Plane):
0.26688
0.41559
Parameter Name:
knal
Estimated Value:
0.078354
Standard Deviation:
0.030372
95% Range (Univariate):
0.0083153
0.14839
95% Range (Support Plane):
0.012347
0.16905
Variance-Covariance Matrix
0.00061996
0.00040206
0.00092247
Correlation Matrix
1
0.53166
1
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APPENDIX C

ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR CALCITONIN IV
AND INHALED PK PROFILES

Table C.1 Calcitonin mean (±SD) plasma concentration vs. time profile data reported in
Buclin et al. after IV infusion.
Time (h)
0
0.25
0.5
0.76
1.01
1.51
2

Mean plasma concentration (µg/L)
0
0.096952
0.11276
0.12175
0.17277
0.0141
0.00399
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SD (µg/L)
0
0.0199
0.025
0.02924
0.038
0.0037
0.0009

A)
// Calcitonin IV One Compartment Model File
IndVars: T
DepVars: CC
Params: VC, k10
//INPUT
Dose=10
TINF1=1
RATEON1=Dose/TINF1
TON1=0
TOFF1=TON1+TINF1
FLAGON1=UNIT(T-TON1)
FLAGOFF1=UNIT(T-TOFF1)
ARATE1=RATEON1*FLAGON1*(1-FLAGOFF1)
MC'=ARATE1-k10*MC
CC=MC/VC
//Initial conditions
B)
T=0
Parameter Parameter Lower
MC=0
Name
Value
Limit
***
VC
3.72
0
k10
17.9
0
C)
Time (h)
0
0.25
0.5
0.76
1.01
1.51
2

Upper
Limit
Infinity
Infinity

Fixed?
Yes
Yes

Predicted plasma concentration (µg/L)
0
0.090789
0.12658
0.14069
0.14626
0.022731
0.003533

Figure C.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist ® for
curve-fitting the mean plasma concentration vs. time profile of calcitonin following IV
infusion.
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Table C.2 Goodness-of-fit statistics and statistical output for calcitonin IV PK profile
curve fitting.
Goodness-of-fit statistics
Weighted Unweighted
Sum of squared observations:
6.72E-08
6.72E-08
Sum of squared deviations:
1.36E-09
1.36E-09
Standard deviation of data:
1.65E-05
1.65E-05
R-squared:
0.97973
0.97973
Coefficient of determination:
0.95156
0.95156
Correlation:
0.9758
0.9758
Model Selection Criterion:
2.456
2.456
Confidence Intervals
Parameter Name:
VC
Estimated Value:
17.921
Standard Deviation:
3.7647
95% Range (Univariate):
8.2433
27.598
95% Range (Support Plane):
5.114
30.728
Parameter Name:
k10
Estimated Value:
3.7232
Standard Deviation:
0.96678
95% Range (Univariate):
1.238
6.2083
95% Range (Support Plane):
0.43438
7.012
Variance-Covariance Matrix
1.42E+01
-3.4649
0.93466
Correlation Matrix
1
-0.95198
1
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Table C.3-A Calcitonin mean (±SD) plasma concentration vs. time profile data reported
in Clark et al. after inhalation from DPI.
Time (h)
0
0.08
0.17
0.33
0.5
1
2
4
6

Mean plasma concentration (µg/L)
0
0.02128
0.04217
0.038
0.03611
0.02
0.00961
0
0

SD (µg/L)
0
0.009
0.0086
0.0131
0.0128
0.0067
0.0067
0
0

Table C.3-B Calcitonin mean (±SD) plasma concentration vs. time profile data reported
in Clark et al. after inhalation from NEB.
Time (h)
0
0.08
0.17
0.33
0.5
1
2
4
6

Mean plasma concentration (µg/L)
0
0.02166
0.03534
0.039
0.04143
0.03083
0.0106
0.0029
0
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SD (µg/L)
0
0.009
0.0086
0.0131
0.0128
0.0067
0.0067
0.002
0

A)
//Calcitonin lung deposition and disposition PK model
IndVars: T
DepVars: CC
Params: Dose, VC, k10, ka, knal
ML'=-(ka+knal)*ML
MC'= ka*ML-k10*MC
CC=MC/VC
//Initial conditions
T=0
ML=Dose
MC=0
***

B)
Parameter Parameter Lower
Name
Value
Limit
Dose
52.9
0
(DPI)
Dose
56.9
0
(NEB)
VC
11.4
0
k10
0.53
0
k12
0.36
0
k21
0.69
0
ka (DPI)
0.06
0
knal (DPI)
2.32
0

Upper
Limit
Infinity

Fixed?

Infinity

Yes

Infinity
Infinity
Infinity
Infinity
Infinity
Infinity

Yes
Yes
Yes
Yes
Yes
Yes

ka (NEB)
knal (NEB)

Infinity
Infinity

Yes
Yes

0.05
1.22

0
0

Yes

C)
DPI
Time (h)
0
0.08
0.17
0.33
0.5
1
2
4
6

Predicted plasma
concentration (µg/L)
0
0.021041
0.035067
0.042564
0.038973
0.017993
0.0021036
0.000019237
1.6529E-07

NEB
Time (h)
0
0.08
0.17
0.33
0.5
1
2
4
6

Predicted plasma
concentration (µg/L)
0
0.016758
0.030866
0.042273
0.043841
0.030332
0.0092892
0.0007408
0.000058635

Figure C.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist ® for
curve-fitting the mean plasma concentration vs. time profiles of calcitonin following
inhalation from DPI and NEB.
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Table C.4-A Goodness-of-fit statistics and statistical output for calcitonin DPI PK profile
curve fitting.
Goodness-of-fit statistics
Weighted Unweighted
Sum of squared observations:
5.47E-09
5.47E-09
Sum of squared deviations:
1.42E-10
1.42E-10
Standard deviation of data:
4.50E-06
4.50E-06
R-squared:
0.97411
0.97411
Coefficient of determination:
0.93887
0.93887
Correlation:
0.97487
0.97487
Model Selection Criterion:
2.3503
2.3503
Confidence Intervals
Parameter Name:
ka
Estimated Value:
0.059249
Standard Deviation:
0.0064283
95% Range (Univariate):
0.044049
0.07445
95% Range (Support Plane):
0.039462 0.079036
Parameter Name:
knal
Estimated Value:
2.3214
Standard Deviation:
0.45545
95% Range (Univariate):
1.2444
3.3984
95% Range (Support Plane):
0.91947
3.7233
Variance-Covariance Matrix
4.13E-05
0.0024008
0.20743
Correlation Matrix
1
0.82003
1
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Table C.4-B Goodness-of-fit statistics and statistical output for calcitonin NEB PK profile
curve fitting.
Goodness-of-fit statistics
Weighted Unweighted
Sum of squared observations:
6.03E-09
6.03E-09
Sum of squared deviations:
7.25E-11
7.25E-11
Standard deviation of data:
3.22E-06
3.22E-06
R-squared:
0.98799
0.98799
Coefficient of determination:
0.96806
0.96806
Correlation:
0.98934
0.98934
Model Selection Criterion:
2.9994
2.9994
Confidence Intervals
Parameter Name:
ka
Estimated Value:
0.045027
Standard Deviation:
0.0029126
95% Range (Univariate):
0.03814
0.061915
95% Range (Support Plane):
0.036062 0.053993
Parameter Name:
knal
Estimated Value:
1.2232
Standard Deviation:
0.1642
95% Range (Univariate):
0.83892
1.6114
95% Range (Support Plane):
0.71777
1.7286
Variance-Covariance Matrix
8.48E-06
0.00036168
0.02696
Correlation Matrix
1
0.75628
1
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APPENDIX D

ORIGINAL DATA SETS FROM CURVE FITTING APPROACH FOR CIPROFLOXACIN
IV AND INHALED PK PROFILES

Table D.1 Ciprofloxacin mean (±SE) serum concentration vs. time profile data reported
in Brunner et al. after IV infusion.
T (h)
Mean serum concentration (mg/L)
SE (mg/L)
0.33
1.3631
0.08793
0.67
0.7819
0.070346
1.00
0.6240
0.035182
1.33
0.5312
0.030769
1.67
0.4244
0.069972
2.00
0.3967
0.026373
2.33
0.3643
0.021978
2.67
0.3366
0.0206374
3.00
0.2996
0.021978
3.33
0.2858
0.030752
3.67
0.2441
0.021978
4.00
0.2257
0.026373
4.33
0.2306
0.026356
4.67
0.2122
0.030752
5.00
0.1891
0.026376
5.33
0.1800
0.021978
5.67
0.1662
0.022356
6.00
0.1757
0.013187
6.33
0.1713
0.021961
6.67
0.1622
0.017582
7.00
0.1391
0.010769
7.33
0.1439
0.012989
7.67
0.1395
0.017582
8.00
0.1536
0.026373
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Table D.2 Macro-rate constants derived from ciprofloxacin IV PK profile reported in
Brunner et al. by using method of residuals.
A (mg/L)
α (h-1)
B (mg/L)
β (h-1)

1.58
2.06
0.51
0.18

The macro-rate constants in Table D.2 were used to calculate initial estimates of k10,
k12, k21 and VC which are reported in Chapter 3.
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A)
// Ciprofloxacin IV Two Compartment Model File
IndVars: T
DepVars: CC
Params: VC, k10, k12, k21
//INPUT
Dose=200
TINF1=0.17
RATEON1=Dose/TINF1
TON1=0
TOFF1=TON1+TINF1
FLAGON1=UNIT(T-TON1)
FLAGOFF1=UNIT(T-TOFF1)
ARATE1=RATEON1*FLAGON1*(1FLAGOFF1)
MC'=ARATE1+k21*MP-(k12+k10)*MC
MP'=k12*MC-k21*MP
CC=MC/VC
//Initial conditions
T=0
MC=0
MP=0
***

B)
Parameter Value
Name
VC
93.2
k10
0.64
k12
1.42
k21
0.86

Lower
Limit
0
0
0
0

Upper
Limit
Infinity
Infinity
Infinity
Infinity

Fixed?
Yes
Yes
Yes
Yes

C)
T (h)
0.33
0.67
1.00
1.33
1.67
2.00
2.33
2.67
3.00
3.33
3.67
4.00
4.33
4.67
5.00
5.33
5.67
6.00
6.33
6.67
7.00
7.33
7.67
8.00

Predicted serum concentration (mg/L)
1.3536
0.8231
0.59845
0.48998
0.42847
0.38949
0.35969
0.33381
0.31144
0.29096
0.27143
0.25379
0.23733
0.22149
0.20713
0.19371
0.18079
0.16907
0.15812
0.14757
0.13801
0.12906
0.12045
0.11265

Figure D.1 A) model file, B) Parameter file and C) Predicted profile of the Scientist ® for
curve-fitting the mean serum concentration vs. time profile of ciprofloxacin following IV
infusion.
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Table D.3 Goodness-of-fit statistics and statistical output for ciprofloxacin IV PK profile
curve fitting.
Goodness-of-fit statistics
Weighted Unweighted
Sum of squared observations:
4.37
4.37
Sum of squared deviations:
0.0094903 0.0094903
Standard deviation of data:
0.021783
0.021783
R-squared:
0.99783
0.99783
Coefficient of determination:
0.99455
0.99455
Correlation:
0.99729
0.99729
Model Selection Criterion:
4.8796
4.8796
Confidence Intervals
Parameter Name:
VC
Estimated Value:
93.249
Standard Deviation:
4.2449
95% Range (Univariate):
84.395
102.1
95% Range (Support Plane):
78.876
107.62
Parameter Name:
k10
Estimated Value:
0.64064
Standard Deviation:
0.036048
95% Range (Univariate):
0.56544
0.71583
95% Range (Support Plane):
0.51858
0.76269
Parameter Name:
k12
Estimated Value:
1.4245
Standard Deviation:
0.14872
95% Range (Univariate):
1.1142
1.7347
95% Range (Support Plane):
0.92091
1.928
Parameter Name:
k21
Estimated Value:
0.8639
Standard Deviation:
0.077395
95% Range (Univariate):
0.70246
1.0253
95% Range (Support Plane):
0.60185
1.126
Variance-Covariance Matrix
18.02
-0.13651
0.0012995
-0.58014
0.0044918 0.022119
-0.19787
0.0021057 0.0086923
Correlation Matrix
1
-0.89207
1
-0.91893
0.83782
1
-0.60226
0.75473
0.75517
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Table D.4 Ciprofloxacin mean (±SD) plasma concentration vs. time profile data reported
in Stass et al. after inhalation from DPI.
T (h)
0
0.5
1
1.5
2
2.5
3
4
6
8

Mean plasma concentration (mg/L)
0
0.04
0.0311
0.02655
0.024859
0.022599
0.02033
0.017514
0.012429
0.00904
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SD (mg/L)
0
0.0101695
0.0101695
0.0067796
8.47E-03
0.0080508
0.0076271
0.0063559
0.0029661
0.004661

A)
//Ciprofloxacin lung deposition and disposition PK model
IndVars: T
DepVars: CC
Params: Dose, VC, k10, k12, k21, ka, knal
ML'=-(ka+knal)*ML

B)

MC'=k21*MP-(k12+k10)*MC+ka*ML

Parameter Parameter Lower
Name
Value
Limit
Dose
16.58
0
(DPI)
VC
93.2
0
k10
0.64
0
k12
1.42
0
k21
0.86
0
ka
0.98
0
knal
0.61
0

MP'=k12*MC-k21*MP
CC=MC/VC
//Initial conditions
T=0
ML=Dose
MC=0

Upper
Limit
Infinity

Fixed?

Infinity
Infinity
Infinity
Infinity
Infinity
Infinity

Yes
Yes
Yes
Yes
Yes
Yes

Yes

MP=0
***
C)
T (h)
0
0.5
1
1.5
2
2.5
3
4
6
8

Predicted plasma concentration (mg/L)
0
0.039072
0.035802
0.029719
0.024721
0.021133
0.018492
0.014705
0.0097214
0.0064798

Figure D.2 A) model file, B) Parameter file and C) Predicted profile of the Scientist ® for
curve-fitting the mean plasma concentration-time profiles of ciprofloxacin following
inhalation from DPI.
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Table D.5 Goodness-of-fit statistics and statistical output for ciprofloxacin DPI PK profile
curve fitting.
Goodness-of-fit statistics
Weighted Unweighted
Sum of squared observations:
0.005357
0.005357
Sum of squared deviations:
6.83E-05
6.83E-05
Standard deviation of data:
0.0029216 0.0029216
R-squared:
0.98725
0.98725
Coefficient of determination:
0.94204
0.94204
Correlation:
0.97792
0.97792
Model Selection Criterion:
2.4481
2.4481
Confidence Intervals
Parameter Name:
ka
Estimated Value:
0.98005
Standard Deviation:
0.11634
95% Range (Univariate):
0.71178
1.2483
95% Range (Support Plane):
0.63264
1.3275
Parameter Name:
knal
Estimated Value:
0.61366
Standard Deviation:
0.10884
95% Range (Univariate):
0.36267
0.86464
95% Range (Support Plane):
0.28863
0.93869
Variance-Covariance Matrix
0.013534
0.0095603
0.011846
Correlation Matrix
1
0.75503
1
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APPENDIX E

MODEL FILE FOR LOCAL LUNG EXPOSURE PROFILE SIMULATION

//Local lung exposure profile/Drug mass remaining in lung vs. time profile simulation
model file
IndVars: T
DepVars: ML
Params: ka, knal
//INPUT
Dose=INPUT DOSE
ML'=-(ka+knal)*ML
//Initial condition
T=0
ML=Dose
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